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1 Introduction 
2. Bifidobacteria 
The disequilibrium between energy intake and expenditure causes obesity (Woods et al. 
1998). The major cause of obesity is a positive energy balance resulting from increased 
dietary energy intake and decreased energy output. Recent studies have showed that 
microbiota can contribute to the development of obesity (Cani et al. 2007). Non-alcoholic 
fatty liver disease (NAFLD) comprises a series of liver injury associated with liver cell fat 
accumulation in the absence of significant alcohol consumption. Non-alcoholic 
steatohepatitis (NASH) an often silent liver disease is a part of the NAFLD and is 
characterized by the presence of excess fat in the liver accompanied by variable liver 
cell inflammation or fibrosis. NASH is often associated with obesity, becoming 
increasingly prevalent both in adults and children (Chalasani et al. 2012; Kleiner et al. 
2005). Ley et al. (2005) indicated, in a rodent experiment that the obesity could be 
connected to an altered gut microbiota. The gut microbiota contributes to the host 
response towards nutrients (Qin et al. 2010; Diamant et al. 2011). During their first year 
of life, normal weight children exhibited a fecal microbiota richer in bifidobacteria but 
poorer in Staphylococcus aureus than children who were subsequently overweight 
(Kalliomäki et al. 2008). Genus Bifidobacterium (B.) are broadly characterized as Gram-
positive, non-motile, catalase-negative and obligate anaerobic bacteria. Bifidobacteria 
are capable of utilizing a variety of complex carbohydrates which are indigestible by the 
host during transit through the gastro-intestinal tract (GIT). Bifidobacterium species are 
common inhabitants of the human GIT of human, different animals and sewage 
(Pokusaeva et al. 2011; Biavati et al. 2006). In human some bifidobacteria can be 
opportunistically pathogenic, such as B. dentium, others are commensal or health-
promoting, also classified as probiotic microorganism like B. bifidum and B. breve (Vitali 
et al. 2007; Bhadoria et al. 2011; Kumar et al. 2012). Bifidobacteria have many 
beneficial effects including protection against pathogens as it plays a role in the normal 
development of the immune system and positive nutritional effect on the intestinal cells 
and the host (Venema et al. 2003). 
In a previous study, B. longum showed a more significant effect in lowering serum total 
cholesterol than a mixed culture of Streptococcus thermophilus and Lactobacillus 
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delbrueckii subps. bulgaricus both in rats and humans. These results suggested that 
some specific strains of bifidobacteria linked to lipid metabolism and body weight may be 
potentially therapeutic when applied for managing obesity (An et al. 2011). Attempts 
have been made to increase the number of biﬁdobacteria in the intestinal tract by 
supplying specific biﬁdobacteria strains and foodstuffs that stimulate the growth of 
Biﬁdobacteria (Kitajima et al. 1997; Lee et al. 1999). It has been proposed that 
alterations in the composition of the gut microbiota known as dysbiosis in the triglyceride 
accumulation and hypercholesterolemia, and that participated in obesity (Neyrinck et al. 
2012). The development of obesity and type 2 diabetes following feeding a high-fat diet 
was characterized by specific changes of the bacterial populations which were 
predominant in the gut microbiota. Yin et al. (2010) concluded that the response of 
energy metabolism to bifidobacteria was strain-dependent. Therefore, different strains of 
bifidobacteria might lead to different fat distributions.  
The overall aim of this study was to evaluate the anti-obesity activity of Bifidobacteria 
strains grown in skimmed milk media on young mice fed a high-fat diet. This is achieved 
by: 
 Isolation of predominant Bifidobacterium species from stools of breastfed infants 
which have been identified as a probiotic. 
 Improved the growth of B. breve and B. longum in skimmed milk media 
supplemented with yeast extract, glucose and oligofructose on different levels that 
increase count number after conservation.  
 Increasing the amount of bifidobacteria in the host intestine.   
 Evaluation of the effect of bifidobacteria strains on weight gain and liver lipid 
accumulation as well as serum triglycerides on young mice fed a high-fat diet. 
 
Early studies of the Bifidobacterium genus 
Henry Tissier isolated bifidobacteria based on his observation of microbiota in the stools 
of breast-fed infants. Tissier named his find Bacillus bifidus communis which is now 
known as bifidobacteria (Tissier 1899; Tissier 1900). Later, Tissier’s isolates were 
named Lactobacillus bifidus following Winslow’s suggestion that they belonged to the 
family of Lactobacillaceae (Holland 1920). The Danish microbiologist (Orla-Jensen 
 13 
 
1924) differentiated the genus bifidobacterium into a separate taxon and showed 
similarities to the genus Lactobacillus that he listed in the seventh edition of Bergey’s 
Manual of Determinative Bacteriology (Breed et al. 1957). Although the cell wall murin 
structure of the bifidobacteria is more similar to Lactobacillaceae than to 
Actinomycetaceae, Bifidobacterium species were included in the family 
Actinomycetaceae of the order Actinomycetales of the Actinomycetes (Kandler et al. 
1974). Further studies have recognized the presence of several multiple biotypes of 
Bifidobacterium, and Dehnart suggested a scheme for the differentiation of these 
bacteria on the basis of their ability of carbohydrate fermentation (Biavati et al. 2000). 
(Reuter 1963) recognized B. bifidum and defined seven species of bifidobacteria. The 
key enzyme, fructose-6phosphate phosphoketolase of hexose pathway fermentation 
was characterized by Scardovi et al. (1965) and later by (Devries et al. 1967). Scardovi 
et al. (1970) started to use the DNA-DNA filter hybridization procedure to recognize DNA 
homology groups among the previously described strains and to recognize new isolates 
from different ecological niches. Rogosa (1974) classified the same name of the genus 
Bifidobacterium in the eighth edition of Bergey’s Manual of Determinative Bacteriology. 
Some corrections were made to the classification after presentation of the 
electrophoresis of soluble cell proteins on polyacrylamide gel as a criterion for 
rearrangement of species’ identification (Biavati et al. 1982). Stackebrandt et al. (1997) 
suggested based on 16S rRNA analysis, a novel hierarchy structure collection of the 
genus Bifidobacteria with the genus Gardnerella into the single family of 
Bifidobacteriaceae in the order of Bifidobacteriales. 
The Bifidobacterium cells have been defined as irregular, non-capsule, non-motile, non-
spore-forming, non-filamentous and Gram-stain posative. Bifidobacteria are anaerobic 
(lacking H2O2 detoxification systems) with an optimum growth temperature of 35–39°C. 
Bifidobacteria show negative reactions for indole fermentation, gelatin hydrolysis, 
catalase (with an exception for B. indicum and B. asteroides when grown in the 
presence of air) and oxidase, where neither release CO2 from carbohydrate fermentation 
nor produce butyric or propionic acids (Baffoni et al. 2013; Biavati et al. 2006). At 
present, the genus of bifidobacterium includes 39 species (Pokusaeva et al. 2011; 
Okamoto et al. 2008).  
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Bifidobacterium cells appear in various morphological forms during isolation and 
culturing. The characteristic shape of bifidobacteria is a rod-shaped form with bifurcated 
Y- and V-forms that occur singly, in clumps or in many-celled chains. Coccoid forms can 
also be seen. The bulge often occurs at one end in the form of a cudgel or spatula and 
sometimes as a branch. Different forms can be found within one species depending on 
the culture conditions (Kojima et al. 1970). The concentration of calcium ions and 
sodium salts involved in the synthesis of the cellular wall results in an increase of 
branches (Glick et al. 1960). In 1992, Biavati et al. suggested that pleomorphism is 
apparently affected by a defective synthesis of the cell wall rather than because of 
degenerative processes and the observed phenomenon of ‘phase variation’. The 
irregular shape is a result of the absence or low concentrations of N-acetylamino amino 
acids (alanine, aspartic acid, glutamic acid, and serine) or sugar (Biavati et al. 2006). 
The cell morphology is affected by different culture conditions and species-specific 
dimensions (Poupard et al. 1973). The colonies are opaque and the shape is mostly 
spherical (Biavati et al. 2006). 
Bifidobacteria can grow in semi-synthetic media-supplemented factors that are used for 
lactobacilli (Poupard et al. 1973). Bifidobacteria are chemoorganotrophs, possessing a 
fermentative type of metabolism. Bifidobacteria show the ability to grow on ammonium 
salts as the sole nitrogen source (Mattarelli et al. 1999). Although there is a 
heterogeneity in the nutrient requirements of bifidobacteria species, riboflavin and 
calcium pantothenate are the main nutrients required for growth while the other water-
soluble (B-complex) vitamins can be synthesized by several strains isolated from 
humans (Trovatelli et al. 1978). Bifidobacterium pseudolongum subsp. globosum shows 
auxotrophy for L-leucine amino acid for plasmid cloning requirement (Mattarelli et al. 
1999). Bifidus factors are able to enhance the growth of bifidobacteria that can be 
classified into oligosaccharides like fructooligosaccharides and glycoproteins such as N-
acetyl-D-glucoseamine or iron-binding proteins such as lactoferrin (Bezkorovainy et al. 
1981); (Pokusaeva et al. 2011a). Bifidobacteria have efficient system enzymes for 
breaking down oligosaccharides and polysaccharides, especially fructofuranosidase 
(Perrin et al. 2001). Bifidobacteria’s ability to simulate oligosaccharides and 
polysaccharides offers competition to the other microorganisms in the intestinal tract 
(Van der Meulen et al. 2004). The cell mass of B. breve 255 was enhanced in a modified 
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MRS media containing 1% (w/v) sodium thiosulphate. The yield biomass of B. breve 255 
was optimized by 37.4°C, pH7.09, inoculum volume 1.97 (ml/100mL), inoculum age 
58.58 hours, carbon content 41.74% and nitrogen content 46.23% (Meena et al. 2011).  
More than 31 different cultural media were created for isolating and enumerating 
Bifidobacterium species from human, animal, environmental and food sources. 
Shigwedha et al. (2013) specified the popular media used for the enumeration of 
bifidobacteria from different sources. They classified the media into five different groups. 
The first group is a non-selective medium (such as MRS and Rogosa), a medium 
without antibiotics but with elective carbohydrate (Acetylglucosamine–Lactose [AL]) agar 
and Liver Cysteine Lactose (LCL) agar, a medium with antibiotics (such as 
Bifidobacterium Iodoacetate Medium (BIM-25) agar, reinforced Clostridial agar with 
Cephalothin and Blood (RCB) and Tomato Casein Peptone Yeast agar (TPCY with 
antibiotics), a medium with propionate (Propionate agar or Beerens agar), and a medium 
with elective substance and/or low pH (Tomato Casein Peptone Yeast agar [TCPY], 
Tomato Casein Peptone Yeast agar [TPCY] with azide, Tomato Casein Peptone Yeast 
agar [TPCY with sorbic acid, TTC-agar and x-Gal medium]. Combinations belonging to 
more than one group are also used—for instance, Bifidobacterium selective [BS] agar, 
Bifidobacterium selective medium [BBM] agar, Modified Rogosa agar, MPN-agar, MRS 
agar with LiCl and antibiotics [MRS-NN], Neomycin Paromomycin Lithium Nalidixic acid 
[NPLN] agar, Raffinose–Bifidobacterium [RB] agar and YN-6 agar). It can be concluded 
from the large variety of the types of media that there is no standard medium for the 
detection of bifidobacteria (Roy 2001). 
Bifidobacteria break down sugars through a metabolic pathway (Figure 1) to acetate and 
lactate for energy production by a system called ‘bifid shunt’. The key enzyme fructose-
6-phosphoketolase (EC 4.1.2.2) is considered to be a taxonomic marker for the family of 
Bifidobacteriaceae.  
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Figure 1: Schematic representation of the main steps of the fructose-6-phosphate shunt in 
Bifidobacterium. 
 
Further enzymes are required to produce energy in the form of ATP from fermentation of 
carbohydrates (Reyes-Gavilan et al. 2005). From the fermented one-molecule glucose 
the bifid shunt pathway of Bifidobacteria produces 2.5 ATP mol more energy than the 
homofermentative group of lactic acid bacteria that produces 2 ATP mol, while 
heterofermentative lactic acid bacteria produces 1 mol of ATP. Bifidobactria can 
assimilate a wide variety of sugars, such as glucose, fructose, galactose, arabinose, 
xylose, ribose, sucrose, lactose, cellobiose, melibiose, gentobiose, maltose, isomaltose, 
raffinose and mannose. In addition, the carbohydrate-derived substrates N-
acetylglucosamine and N-acetylgalactosamine, mucin and pectin could be assimilated 
(Pokusaeva et al. 2011; Reyes-Gavilan et al. 2005; Bezkorovainy et al. 1989). 
The key enzyme (fructose-6-phosphate phosphoketolase F6PPK) cleavages hexose in 
the bifid shunt pathway to erythrose phosphate and acetyl phosphate leading to an 
increase in lactic acid and acetic acid in a theoretical ratio of 1:1.5 which may change 
according to the assimilated carbon source and the species type (Palframan et al. 
2003). Xylulose phosphates are formed from erythrose and fructose phosphates 
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metabolite through the consecutive activity of transaldolase and transketolase 
increasing the ratio of acetic acid to lactic acid. The glyceraldehyde 3-phosphate 
generated enters the Embden-Meyerhoff-Parnas pathway (Ballongue 1998). Some of 
the pyruvate is converted to formic causing a reduction of acetate to ethanol (Lauer et 
al. 1976; Schramm et al. 1958). 
Due to the lack of electron acceptors in anaerobic organisms, the organic substance is 
subjected to a series of oxidation and reduction reactions, and hydrogen peroxide is 
accumulated. The deficient scavenging enzymes in bifidobacteria such as superoxide 
dismutase, catalase, and peroxidases are present in aerobic organisms that cannot 
eliminate lesions in proteins and nucleic acids of oxygen toxicity (Imlay 2008). It has 
been proposed that the sensitivity of Bifidobacterium species to oxygen is due to the 
existence production system of H2O2 and the absence of detoxification systems of H2O2. 
The inhibition of an essential metabolic enzyme of bifidobacteria in the presence of 
oxygen may be due to the inactivation of pyruvate: Ferredoxin oxidoreductase (Pan et 
al. 2001). Shimamura et al. (1990) suggested that the activities of Nicotinamide Adenine 
Dinucleotid Hydrogen (NADH) oxidative enzyme are very low in Bifidobacterium species 
in comparison to the activities that are found in O2-tolerant species. The increased 
activities of NADH peroxidase correlates with the increase in hydrogen peroxide 
decomposition (Talwalkar et al. 2004). Most of Bifidobacterium spp. grew successfully 
without inhibition in the presence of 5% O2 but stopped growing in 10% O2 while B. 
boum JCM1207 grew well in the presence of 20% O2. The degree of tolerance to 
oxygen depends on the particular type of Bifidobacterium species and culture medium. 
The Bifidobacterium spp. can be classified into four groups; O2-hypersensitive, O2-
sensitve, O2-tolerant, and microaerophilic. The species belong to the O2-tolerant and 
microaerophilic groups and are all isolates of nonhuman sources: sewage (B. minimum), 
bovine rumen (B. boum and B. thermophilum), and (B. astroides and B. indicum) from 
the honey-bee hindgut (Kawasaki et al. 2006).   
Bifidobacteria belong to the phylum Actinobacteria, class Actinobacteria, order 
Bifidobacteriales, and family Bifidobacteriaceae (Garrity et al. 2007; Otieno 2011). 
Bifidobacteria are distinguished according to phylogenetic characteristics, belonging to 
the high G-C (42-67%) and usually higher than 55% of the content are different from the 
Lactobacillus genera. Consequently, lactic acid is one of the main fermentation products 
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of bifidobacteria; therefore, they were included in the group of lactic acid bacteria, which 
share the same features as that of the host habitat. Depending on a number of general 
fermentation product features, bifidobacteria and lactic acid bacteria are the most 
commonly used probiotic microogranisms in the food industry (Bhadoria et al. 2011). 
The efficacy of organic acid production of Bifidobacterium species toward pathogens is 
greater than the effects of lowering the pH value alone. When acetic and lactic acid have 
been used for pH value reduction, the growth inhibition of Salmonella enterica 
Typhimurium and E. coli was greater than hydrochloric acid indicating the involvement of 
other mechanisms (Makras et al. 2006).   
The phenotypic identification of bifidobacteria depends on the morphological features 
and evidence for the presence of Fructose-6-phosphate phosphoketolase that is present 
in all bifidobacterial species. The ability of enzymes to utilize various saccharides in a 
biochemical test allows the clear identification of an isolate as a Bifidobacterium species 
based on a simple carbohydrate fermentation pattern (Mitsuoka 1969; Scardovi et al. 
1969). Moreover, chemotaxonomic methods analysed the protein structure of specific 
cellular compounds. Whole-cell proteins profiling by Sodiumdodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) was used for differentiating B. 
adolescentis, B. bifidum, B. breve, B. dentium and B. longum which were isolated from 
adult faeces, as well as for the identification of B. lactis from European probiotic 
products (Vitali et al. 2007). Proteomics identification is dependent on the protein 
characteristics and fingerprinting maps of cytoplasmic peptides that are generated by 
matrix-assisted laser desorption ionization-time of flight mass (MALDI TOF). Genotypic 
identification is based on information obtained from the genome or from specific genes 
rather than the expression products as in the case of phenotypic identification 
(Angelakis et al. 2011; He et al. 2007).  
The rRNA sequence analysis is particularly used to assign relatedness of homology with 
the most related species among the genera. Molecular phylogeny is derived from a high 
correlation of elongation factors that are involved in the translation of diverse molecules 
of 16S RNA genes coding for 16S rRNA or 16S rDNA (Woese 1987). Several genotypic 
methods are based on the rule of polymerase chain reaction (PCR) which makes it 
possible for the specific amplification of targeted DNA fragments by using 
oligonucleotide primers. The generated oligonucleotide species-specific primer targets 
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sequences of the 16S rRNA gene for detection and identification of bifidobacteria to the 
genus and species or strain level (Kaufmann et al. 1997). The DNA sequence analysis 
is better than any other taxonomic method and is based on the amplification and cloning 
of 16S rRNA gene of DNA or RNA (cDNA). Selected clones from the microbial 
community are then sequenced and analysed in silico ‘computer simulation’. 
Phylogenetic accession of bioinformatics tools are then applied which align and affiliate 
the clones to the closest relatives. Finally, the aligned sequences are grouped into a 
structure named molecular species or visualized in a phylogenetic tree. The molecular 
species either belong to a cultivated bacterial species or a bacterial species that has not 
yet been cultivated (Charalampopoulos et al. 2009; Stackebrandt et al. 1994). 
1.1 Obesity 
Obesity is one of the greatest public health problems and is caused by an excessive 
accumulation of fat to the point that it poses a risk to the individual’s health (WHO 2011). 
The prevalence of obesity has noticeably increased in the past few decades and is 
responsible for more healthcare costs in comparison to any other medical condition. 
Obesity and overweight are mostly defined on the basis of body mass index (BMI). 
Overweight can be defined with a BMI of 25 kg/m2 or higher while a BMI greater than or 
equal to 30 kg/m2 is referred to as obesity. According to the WHO (2005), BMI is 
calculated as weight in kilograms divided by the square of height in metres, where the 
greater the BMI, the greater the hazard of comorbidities is; including diabetes mellitus, 
hypertension, obstructive sleep apnoea, several types of cancers, dyslipidemia, 
cardiovascular disease, and overall mortality. Obesity is a public health problem that has 
triggered worldwide concern. According to the World Health Organization (WHO), there 
are 2.3 billion obese people aged 15 years and above across the world; furthermore, 
over 700 million are expected to be obese by 2015 (Chan et al. 2010).  
Overall, the policies for production of healthier food environments are recommended as 
a high priority for obesity prevention across the globe, but until recently, little action has 
been taken on this issue (Swinburn et al. 2013). The prevalence of overweight and 
obesity has been observed in the past few decades in many countries. It revealed that 
more than half of the American population are overweight and more than 30% are obese 
(Huttunen et al. 2013; Ogden et al. 2007). According to the German Health Interview 
and Examination Survey for Adults (Studie zur Gesundheit Erwachsener in 
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Deutschland), the percentage of overweight adults in Germany has not increased during 
the last decade but remained at a constantly high level, while the prevalence of obesity 
showed an upward trend, especially among young adults. Present information on the 
prevalence of overweight and obesity among German adults is not only based on the 
BMI index alone but also on the analyses of waist and hip circumference measurements 
(Mensink et al. 2013). An imbalance between energy intake and energy expenditure 
causes obesity which is not yet completely understood since it involves both genetic and 
environmental factors (Di Gioia et al. 2014). The reasons for going beyond obesity seem 
to be varied and involve genetic background, disequilibrium of energy homeostasis, a 
sedentary lifestyle, and other environmental factors (Friedman 2009). Nowadays, some 
authors consider obesity to be a transmissible disease because maternal obesity 
predisposes children to obesity in adulthood (Lawlor et al. 2006). The prevalence of 
obesity can become a worldwide epidemic among children and adolescents. In some 
studies, the association of obesity with a specific profile of the bacterial gut microbiota 
contributed to individual bacterial species and whole microbial communities (Tennyson 
et al. 2008). 
1.2 Gut microbiota 
Several factors cause obesity such as alterations in the body’s regulation of energy 
intake, expenditure, and storage. Evidence from studies on animal models suggests that 
the gut microbiota influences nutrient consumption and energy regulation (DiBaise et al. 
2008). The observations of studies on obese mice have been correlated with higher 
levels of Firmicutes and lower levels of Bacteroidetes phylum in comparison with lean 
examples. The mutated ob/ob mice were characterized by a 50% lowering of the amount 
of Bacteroidetes and a relative increase in Firmicutes for more than 5,000 bacterial 16S 
RNA gene sequences analysis from the gut microbiota compared to lean mice. This 
condition increases fermentation, facilitating more energy extraction in the host. 
Furthermore, feeding a high-fat diet to the mice showed a change in the microbiota 
structure with a decrease in the amount of predominant Gram-positive groups such as 
Bifidobacterium species (Ley et al. 2006). Moreover, the gut microbiota of lean 
individuals is more diverse than that of obese individuals (Turnbaugh et al. 2009).  
The increase in energy consumption of less than 1% in comparison to the daily energy 
expenditure can cause an increase in body weight and metabolic syndrome in the long 
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term ‘through several years’ (Hill 2006). Gut microbiota raises the inhibition of fasting-
induced adipose factor (FIAF). FIAF is one of the angiopoietin-like proteins expressed in 
the differentiated gut epithelial cells, liver and adipose tissue. The consequence of FIAF 
inhibition is the increased expression of lipoprotein lipase (LPL) activity that leads to a 
higher cellular gain of fatty acids and accumulation of greater fat storage in adipose 
tissue (Bäckhed et al. 2004; Flint et al. 2008). As a result, germ-free mice are resistant 
to diet-induced obesity. Germ-free mice were protected from gaining more weight and 
fat mass in comparison to the conventional mice when both were fed a (western diet) 
high-fat/high-carbohydrate diet. Surprisingly, another study revealed that germ-free mice 
as well as conventional mice had the same energy content in their faeces when both 
groups were fed a high-fat diet (Cani et al. 2009). The study result has not suggested 
more energy harvest from the high-fat diet in the conventional mice in comparison to the 
germ-free mice. The author proposed a mechanism according to which the gut 
microbiota could have participated in the regulation of AMP-activated protein kinase 
(AMPK) activity and the oxidation of fatty acids. AMPK activity is higher in the muscle 
even in the absence of gut microbiota, produces higher phosphorylation of its specific 
target acetyl-CoA carboxylase (ACC) and reduces the production of malonyl-CoA. The 
reduction of malonyl-CoA raises carnitine palmitoyl transferase-1 (CPT-1) which 
stimulates mitochondrial fatty acid oxidation, and therefore, the experiment result may 
be considered to be a bacterial-related mechanism more than energy harvesting that 
results in diet-induced obesity (Bäckhed et al. 2007). 
A clinical trial has found that an increase in the accumulation of fat is the result of not 
only a positive energy balance and decreased physical activity, but also because of 
specific nutrition components linked to the host’s inflammatory state and the upward shift 
of the aggressive gut microbiota (Huang et al. 2013). Positive correlations have been 
found between energy intakes and plasma lipopolysaccharids (LPS) levels. LPS is a 
compound derived from the cell walls of Gram-negative bacteria which are members of 
the families Enterobacteriaceae and Desulfovibrionaceae in the phylum Proteobacteria. 
A high level of LPS is defined as metabolic endotoxemia which is related to gut, hepatic, 
and adipose tissue inflammation and the symptoms are more apparent with a high-fat 
diet rather than a normal chow diet in mice. An endotoxin activity of the previous 
pathogen families is a thousand-fold more compared to LPS from the family 
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Bacteroideaceae in the phylum Bacteroidetes (Chen et al. 2014; Zhao 2013). Alteration 
of the composition of the gut microbiota may contribute to the prevention as well as to 
the therapy of obesity (Vael et al. 2011). The analyses of intestinal microbiota 
composition have revealed that the plasma LPS concentrations correlate negatively with 
the dominant Gram-positive groups Bifidobacterium spp. and Eubacterium rectale, and 
Clostridium coccidioides groups. Moreover, the administration of Bifidobactrium spp. 
presented the ability to significantly reduce the content of intestinal endotoxin of the 
mice given high-fat meals (Cani et al. 2007). The altered gut microbiota in obese cases 
could have contributed to low-grade inflammation. A high-fat diet fed to mice causes 
metabolic endotoxemia, low-grade inflammation and increases macrophage infiltration in 
adipose tissue. The circulation of inflammatory markers are elevated such as IL-6, TNF-
a, IL-8, IL-10 and these inflammatory factors are known to be involved in insulin 
resistance and excessive hepatic and adipose tissue lipid storage (Cani et al. 2007; Ley 
et al. 2006). 
Bifidobacteria are present in the healthy neonate intestine after two to five days of birth 
and their levels rise within one week up to 99% of the amount of faecal flora (Mitsuoka 
1984). Studies of bifidobacteria on human health have revealed their capability to 
adhere to the intestinal mucosa resulting in an inhibitory effect against a variety of 
enterotoxigenic, enteropathogenic and diarrheagenic bacteria (Bernet et al. 1993; 
Gleinser et al. 2012). Bifidobacteria spp. are considered to be probiotic and could 
stimulate the immune system and increase bioavailability of essential minerals that 
assist in digestion and nutrient absorption (Kumar et al. 2012). Probiotics are organisms 
that do not necessarily have a phylogenetic relation to one another, and are, therefore, 
best defined functionally rather than taxonomically (Rossi et al. 2011). Probiotics are 
defined as ‘live microorganisms, which when administered in adequate amounts, confer 
a health benefit on the host’ (FAO/WHO 2001). Probiotic is also known as a prepared 
product including specific microorganisms in viably adequate numbers that are able to 
exert an influence on the microflora in the host with improved health effects (de Vrese et 
al. 2008).    
In Japan, the first applied research on Bifidobacteria as a probiotic started in the 1950s. 
The Morinaga Milk Industry Company advanced ‘bifidus®’-fermented milk products 
containing Bifidobacterium longum and Streptococcus thermophilus. Later, technologies 
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were launched so that the market products by 1978 contained Bifidobacteria such as 
Mil-Mil®-fermented milk products that contained Bifidobacterium breve, Bifidobacterium 
bifidum and Lactobacillus acidophilus which had been proved to lead to an improvement 
in the health of the general public by Yakult® in Japan (Ishibashi et al. 1993). The 
probiotic prepared products that contain bifidobacteria are varied depending on the 
different dairy products. These days, commercial probiotic products contain a single 
genus Bifidobacterium or in combination with other lactic acid bacteria such as 
lactobacilli and Streptococcus thermophiles. The genus Bifidobacterium have 
encompasses potential probiotics: B. adolescentis, B. animalis subsp. lactis, B. bifidum, 
B. breve and B. longum subsp. infantis and B. longum subsp. longum. The probiotic 
products containing bifidobacteria contribute to a large share of the market value, with 
approximately $1.3 billion in Europe alone (Leatherhead Food Research Association 
2001).  
  
 24 
 
2. Material and Methods 
2.1. Subjects and sampling 
The stools from sixteen healthy breastfed, infants were collected in sterile vials. None of 
the infants suffered from gastrointestinal or any major illness or received antibiotic 
therapy. The sampling was approved by the children’s hospital (Kinderklinik Giessen), 
and their parents’ agreements were obtained. All samples were delivered to the 
laboratory which occurred within half an hour after collection.  
2.2. Pre-reduced peptone water preparation  
Pre-reduced peptone water (g/100ml) was prepared by weighing (Mettler AE163, 
Germany) peptone 0.1 g (Merck, Darmstadt, Germany), NaCl 0.85 g (CarlRoth, 
Germany), L-Cycteine-HCl 0.05 (Sigma, Japan) and dissolved it in deionized distilled 
water. The contents were mixed well using a magnetic stirrer at 300 rpm/5 min (Heidolph 
MR3001, Germany) and adjusted to pH: 7. After separating pre-reduced peptone water 
in test tubes and containers, the proper diluents were sterilized by autoclaving (Webeco-
Wolf, Germany) at 121°C for 15 min (Tzortzis et al. 2005). 
 
List of instruments  
Anaerobic Gas Jar BBL-Difico, USA 
Autoclave  Webeco-Wolf, Germany 
Balance Mettler AE163, Germany 
Centrifuged Biofuge primor, Heraeus-Germany 
Contrast Phase Microscope Axiophot 2–ZEIZZ, Oberkochen–Germany 
Freeze-dryer Lyova GT2, Steris-Germany 
Magnetic Stirrer Heidolph MR3001, Germany 
pH-meter Heidolph, Germany 
Spectrophotometer  Thermo-Spectronic-Genesys 10UV, Fisher, USA 
Steam Boiler  Medizin & Lab. Tech. Fritz Goessner, Hamburg-
Germany 
Thermal Cycler PCR BioRad, Germany 
UV-light Bands visualizer BioRad Gel Doc2000-Germany 
Vortex  Heidolph-real, Germany 
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List of materials  
ALT kit  Alanine aminotransferase 
CaCl2.6H2O Oxoid Ltd. Basingstoke, UK 
CO2  gas generator kit Anaerocult A, Merck-Darmstadt, Germany 
Control diet (C1090-10) Altromin-Spezialfutter, Germany 
DNA marker Fermentas-Thermo Scientific, Germany 
DNeasy blood and tissue kit Qiagen, Hilden, Germany 
EDTA Merck- Darmstadt, Germany 
Glucose Merck, Darmstadt-Germany 
High fat diet (C1090-70) Altromin-Spezialfutter, Germany 
K2HPO4 Oxoid Ltd. Basingstoke, UK 
KH2PO4 Oxoid Ltd. Basingstoke, UK 
L-Cysteine-HCl Sigma, Japan 
Male C57BL/6JRj mice Janvier, 53941-ST-Berthevin, France 
MgSO4.7H2O Oxoid Ltd. Basingstoke, UK 
Micro-filter FP30/0.2CA-S Whatman, Germany 
MRA agar Merck- Darmstadt, Germany 
Mupirocin Sigma, USA 
NaCl CarlRoth, Germany 
Oligofructose Merck, Darmstadt-Germany 
Oligofructose Spennrad, Germany 
Peptone Merck, Darmstadt, Germany 
Reflotron Analyser Roche Basel, Switzerland 
Skim milk Merck, Darmstadt-Germany 
 
2.3. Media composition 
Empty screw cup bottles (100ml) were autoclaved (Sanoclav-Wolf, Germany) at 121°C 
for 20 min and filled with 30, 40 and 80 ml deionized water in Erlenmeyer flask. Weighed 
30, 40 and 80 mg mupirocin antibiotic (Sigma, USA) and transferred into Erlenmeyer 
flasks contained 30, 40 and 80 ml. The solutions were sterilized through a 0.2 µm filter 
(FP30/0.2CA-S Whatman, Germany). The antibiotic stock solutions for three different 
concentration mupirocin MRS agar media were stored in the fridge (Ferraris et al. 2010). 
Three selective 30, 40 and 80 mg/l mupirocin MRS media for Bifidobacteria were 
prepared by dissolving 74.5 g of MRS (Merck- Darmstadt, Germany) media and 0.5 g L-
Cysteine-hydrochloride in one Liter of deionized water. Complex agar media 
composition of MRS was (Casein peptone 10 g, Yeast extract 5 g, D-glucose 20 g, KH-
2PO4 (6 g), NH4-Citrate 2 g, Tween 80 (1 ml), Na-Acetate 15 g, MgSO4 (0.575 g), Fe+3-
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sulfate 0.034 g, MnSO4 (0.12 g), Agar-Agar 15 g. The bottles were steamed for one hour 
at 100°C as recommended by manufacturer. The medium was cooled to approximately 
65°C and 1.3 ml per liter of acetic acid 96% was added, while the pH value was 
approximately 5.5. Three different concentrations of mupirocin were added and the final 
mupirocin MRS media were poured into the plates (Thitaram et al. 2005; Ferraris et al. 
2010). 
A sample of one gram of feces was dissolved in sterile 100 ml pre-reduced peptone 
water and vortexed for 5 min (Heidolph-real, Germany). Serial dilutions of samples were 
prepared and the 10-5 _ 10-7 dilutions was spread on MRS agar plates in triplicate. All 
plates were incubated anaerobically using anaerobic gas jars (BBL-Difico, USA 
containing gas packs), and added 35 ml of distilled water was added for the production 
of an anaerobic environment (Anaerocult A, Merck-Darmstadt, Germany). Oxygen binds 
quickly and completely, creating an oxygen-free environment and a CO2 atmosphere 
generates in a 2.5 liter anaerobic jar. Plates were incubated for 3 days at 37°C. After 
incubation on the mupirocin (80 mg/L) MRS media, white colonies were counted.  
The morphology of bifidobactria growth was examined by contrast phase microscopy 
(Axiophot 2–ZEIZZ, Oberkochen–Germany). After incubation white colonies were 
counted from (80 mg/l) mupirocin MRS media. Several typical colonies (2-5 mm 
diameter) were picked randomly from plates and sub-cultured on MRS medium and 
incubated anearobically at 37°C for three days.    
2.4. Identification of Bifidobacteria 
Single colonies (2-5 mm diameter) formed on the 80 mg/L mupirocin MRS media were 
picked with a sterilized toothpick and suspended in 1µl PCR special water. The 
identification of typical morphological shapes of bifidobacteria based on phenotypic traits 
was performed using contrast phase microscopy technique (Matsuki et al., 2003). 
Morphological observations were smeared for identification typical bifidobacteria shape 
based on phenotypic traits by contrast phase microscopy technique (Matsuki et al., 
2003). The suspended colony mixed with 180 μl TE buffer (10 mmol/L of Tris–HCl, 1 
mmol/L of EDTA; pH 8) containing lysozyme (1mg/mL) and incubated for 1 h at 37°C. 
Finally, 10 μl proteinase K was added to the suspension and incubated for 2 h at 56 °C. 
DNA was subsequently isolated using the DNeasy blood and tissue kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions.  
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The PCR reaction mixture consisted of 2.5 µl buffer (10mM Tris-HCl (pH7.6) and 1mM 
EDTA), 2.5 µl mM dNTP’s, 0.5 µl MR Primer MrF/MrR were primer 1(10 p mol) and 0.5 
µl primer 2(10 p mol), 17.9 µl water and Tag- Polym + 1 µl DNA. The marker used 
(Lambda DNA/ EcoRI+ Hind III Marker, Fermentas-Thermo Scientific, Germany) on the 
site 1500 bp (16.3ng/0.5 µl) 3.3%. Water and E. coli were negative and positive control 
respectively. The thermal cycling (BioRad, Germany) conditions were an initial 
denaturation at 95 °C for 5 min, denaturation at 95 °C for 45 sec, annealing at 57.3 °C 
for 45 sec, extension at 72 °C for 2 min, repeated for 29 cycles, and final extension at 72 
° C for 4 min. For the detection bands used agarose gel, 0.5 µg/Lane, 8 cm length gel, 
1xTAE, 7v/ cm and 45 min). Agarose gel prepared 1% (0.8g / 80ml H2O) and the 
solution heated in microwave with high power energy and poured into the device 
chamber with wells temple maker (comb). After solidified gel sampled in each well mixed 
the dye with glycerol to residue the dye in the button of wells. Bands visualized with 
ethidium bromide (0.5 μg/mL) under UV light (wavelength 260 nm, BioRad Gel 
Doc2000-Germany) (Vlokova et al. 2004).  
These two isolates were identified as B. breve M4A and B. longum subsp. longum FA1 
by the amplification and sequencing of the 16S rRNA gene using the oligonucleotide 
primers EUB9F (5`-GAGTTTGATCMTGGCTCAG-3') and EUB1492R (5`-
ACGGYTACCTTGTTACGACTT-3') (Lane 1991). The PCR reactions were performed as 
described by Kampmann et al. (2012) and the amplicons were sequenced by the 
company LGC Genomics (Berlin, Germany). Next relatives’ sequences were obtained by 
homology searches using BLAST algorithm available at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi and the NCBI database. The accession number 
was CP006716.1 and KM577186.1 for B. breve M4A and B. longum subsp. longum 
FA1, respectively.  
Bifidoacteria subspecies were identified by growth on basal medium. The medium 
consisted of (g/l): peptone water (Oxoid Ltd. Basingstoke, UK) 2, yeast extract (Oxoid) 2; 
NaCl, 0.1; K2HPO4, 0.04; KH2PO, 0.04; MgSO4.7H2O, 0.01; CaCl2.6H2O, 0.01; NaHCO3 
2,; L-cysteine HCl (Sigma) 0.5, and (1% w/v) media were tested with glucose, L-
arabinose and ribose (filter sterilized and added after autoclaving). The component 
media were dissolved in and then were flashed CO2/N2 gas into 10 ml cupped bottles for 
5 min. The bottle media were further autoclaved at 121°C for 20 minutes, once cooled 
 28 
 
the carbohydrates were filtered and added to the media to make an overall 
concentration of 1% (w/v). From MRS broth medium grown, one ml of B. longum subsp. 
longum FA1 was injected aseptically into each tube and incubated at 37°C. Each 
species was grown on each carbohydrate in triplicate. A blank containing medium with 
no added carbohydrate was also inoculated for each bifidobacteria species in triplicate, 
in order to take into account any carryover of glucose. The growth was measured 
(Thermo-Spectronic-Genesys 10UV, Fisher, USA) at a wavelength of (650 nm) at 0, for 
72 hours post inoculation (Palframan et al. 2003; Sakata et al. 2002). 
2.5. Samples preparation  
Special attention was paid to the beginning of the early stationary phase. The optical 
densities were measured of B. longum subps. longum FA1 and B. breve M4A cultures 
versus time to obtain maximum growth curves. The Bifidobacterium strains incubated 
until the stationary phase were reached in MRS broth media. In the cup 100 ml bottles 
5% starter culture was flashed with N2/CO2 gas for 5 min and incubated at 37 ºC for 72 
hr. The growth of the cells was followed by measuring the pH (pH-meter Heidolph 
MR3001, Germany) and optical density of the culture at 580 nm using a 
Spectrophotometer (Thermo Spectronic Genesys 10UV, Fisher -USA) in three different 
times (Trsic-Milanovic et al. 2001).  
The culture strains of 100 ml MRS broth media in their stationary phase were 
centrifuged (Biofuge primor, Heraeus-Germany) at 2500 × g for 10 min at 4 ºC. The 
supernatant was discarded and the concentrated cells were suspended in 20 ml of skim 
milk (10%) and glucose (5%) media (Merck, Darmstadt-Germany).The medium was 
steamed at 100 ºC for 30 min (Medizin & Lab. Tech. Fritz Gossner, Hamburg-Germany). 
The suspension was separated into 1 ml for each vial. The first phase was lyophilization 
by freezing the vials at -18 ºC overnight and the second phase was lyophilizion (Lyova 
GT2, Steris-Germany) by freezing at -18 ºC, vacuum -2.7 mbar for 14 hour. After freeze 
drying, the vials were sealed under vacuum and stored in a refrigerator (Trsic-Milanovic 
et al. 2001; Carvalho et al. 2004). 
The viable cells (CFU/mL) of bifidobacterium strains were enumerated by the MRS agar 
plate count method after dilution in pre-reduced peptone water. The plates were 
incubated under anaerobic conditions at 37 ºC. The colonies were enumerated and 
recorded as colony forming units per milliliter from lyophilized strains by added 1 ml 
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sterilized distilled water into each lyophilized vial for 30 min. The cultures obtained after 
suspension of lyophilized bacterial cells were diluted in pre-reduced peptone water. The 
survival rates of the cultures after lyophilization were estimated in terms of the number of 
surviving cell counts. The results were arithmetic means of three measurements. 
After 6 months of storage growth activity of freeze-dried strains were measured by 
enumerated on MRS agar plates. Freeze-dried preparations were rehydrated with 1 mL 
of sterile water into each lyophilized vial for 30 min, diluted and plated. After incubation 
of the plates under anaerobic conditions as described above the survival rates of the 
cultures after lyophilization were estimated in terms of the number of surviving cell 
counts recorded as colony forming units per mL (CFU/mL). The results were arithmetic 
means of three measurements. 
2.6. Culture media  
For growth improvement and better survival of B. longum subsp. longum FA1 and B. 
breve M4A the strains were cultured in 10% reconstituted skim milk media which was 
supplemented with different concentrations of two carbohydrates and yeast extract. For 
this, skim milk (10%) powder was dissolved in distilled water and supplemented with 
0.3% or 0.6% yeast extract and oligofructose or glucose at different levels (1%, 2% and 
3%). Skim powder (10%) without addition was used as control. The skim milk media was 
heat treated at 110˚C for 10 min. Skim milk media were inoculated with a 10% (v/v) B. 
longum subsp. longum FA1 and B. breve M4A culture after activation of lyophilized 
culture and were incubated anaerobically for 48 h at 37°C. Skim milk media samples 
were withdrawn for pH and turbidity measurements. For the enumeration of viable cells, 
skim milk media were serially diluted in 0.1% (w/v) sterile pre-reduced peptone water 
and plated in triplicate onto MRS agar. Plates were incubated anaerobically at 37°C for 
3 days. Viability was expressed as log CFU/mL. 
An aliquot of skim milk was taken at intervals (1, 5, 25, 35, 45 hours) and diluted (1:10 
v/v) with 0.2% (w/v) EDTA, (pH 12.0) and turbidity was measured (Thermo-Spectronic-
Genesys 10UV, Fisher, USA) at 640 nm. Un-inoculated milk media were diluted with 
0.2% (w/v) EDTA and used as a blank. Specific growth rate (µ) for each culture was 
calculated using the following equation: µ= (lnX2 - lnX1) / (t1 - t2), where X2 and X1 
corresponds to the cell density at time t2 and t1. Doubling time (Td) was calculated as: 
Td = ln2 / µ (Shin et al. 2000). 
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In order to obtain the desired number of bifidobacterium strains, the medium was 
supplemented with carbohydrates to enhance its growth and survival. Skimmed milk 
powder containing 10% solids (Merck) was reconstituted in distilled water. Skimmed milk 
base (containing 0.3% yeast extract) was supplemented with 3% (w/v) oligofructose for 
culture of B. longum subsp. longum FA1 and 3% glucose for B. breve M4A. The media 
were separated in capped bottles containing 10 mL media, flashed with CO2/N2 gas into 
bottles and sterilised by autoclaving at 121°C for 10 min, and inoculated with 10% (v/v) 
B. longum subsp. longum FA1 or B. breve M4A cultures after the activation of each pure 
lyophilised culture for 24 h. The cultures were incubated anaerobically at 37°C, and the 
pH was adjusted: ~5 mL samples were withdrawn every 16 h for analysis. 
2.7. Design of the animal experiment 
An obesity-inducing high-fat diet leads to hepatic steatosis (Yaqoob et al. 1995). The 
induction of obesity is most effective when started at a young age and continued for 
several weeks (Peckham et al. 1962). 
During the first week of the study, mice in the high fat diet-B. longum subsp. longum FA1 
(HFD-FA1) and high-fat diet B. breve M4A (HFD-M4A) groups were given a simple 
control diet for adaptation. From week 2 to 6 both groups were supplemented with B. 
breve M4A and B. longum subsp. longum FA1 with oligofructose administered by 
gavage orally. A combination of prebiotics and probiotics was used in order to increase 
the survival of the bifidobacteria in the intestine (Manning et al. 2004). A third group 
received a high-fat diet only (HFD).  
The interaction between body composition and nutrition differs among mouse species. 
In addition, different diets elicit different reactions towards obesity among mice (Jürgens 
et al. 2006). The effects expected in the current study were estimated according to 
(Kondo et al. 2010), who performed a study for >8 weeks but detected effects after 6 
weeks. The minimum number of mice was calculated (1) based on a significant 
difference in epididymal fat pad between the control and B-3H groups. (2) Significant 
differences in weight gain between the control and Bifidobacteria breve 3H groups were 
identified after 6 weeks. 
The alpha error was set at 0.05 (two-sided) and the tolerated beta error was 0.2. No 
correction for multiple comparisons was performed, and calculations were based on 
parametric tests (one-way ANOVA with LSD post hoc test). The calculations were 
 31 
 
performed using ‘3.1 GPower©’ (University of Duesseldorf, Germany). Six animals per 
group were needed for the minimum sample size based on the above assumptions. In 
addition, variance heterogeneity might result in higher scatter of the measured values. 
Therefore, we increased the number of mice per group to seven. 
2.8. Establishment of animal experiment 
The district president of Giessen approved the study protocol. All experiments were 
performed under specific pathogen-free conditions. Mice were purchased and housed in 
specific barrier facilities according to the Federation of Laboratory Animal Science 
Associations (FELASA) recommendations. Each cage was closed using a filter top and 
was ventilated individually with modified barrier-systems (individually ventilated cages-
IVC). Cages were only opened under laminar flow conditions at the cage changing 
station. 
Male C57BL/6JRj mice (Janvier, 53941-ST-Berthevin, France) aged six weeks were 
divided randomly into three groups of seven mice. Mice were maintained at 22 ± 2ºC 
with 60 ± 5% relative humidity, a 12-h light/dark cycle and food ad libitum. All mice were 
fed the control diet (C1090-10-Altromin-Spezialfutter, Germany) for one week to stabilize 
their metabolism. The diet contained 10 energy percent fat, 71% carbohydrates, and 
19% protein. The control and treatment groups were fed a high-fat diet (C1090-70-
Altromin-Spezialfutter, Germany) to induce obesity for six weeks. In the high-fat diet 
70% of energy were derived from fat, 15% from carbohydrates, and 15% from protein. 
Table 1 indicates the principle composition of both diets.  
The drinking water of mice in the intervention groups (HFD-FA1 and HFD-M4A groups) 
was supplemented with 0.1 g/day oligofructose (Spennrad, Germany) based on a water 
consumption of 4 mL/day per mouse (25g/L oligofructose in water). The purpose of 
oligofructose supplementation was to aid the administered bifidobacteria to survive and 
adhere to mice intestinal mucus. The capability of bifidobacteria strains to adhere to the 
host intestinal mucosa is necessary for therapeutic manipulation and the adhesion has 
the capacity to be a strain dependent (Collado et al. 2005). Bifidobacteria administration 
was started by the second week of the experiment. The administration was given in the 
light phase.   
A single dose of 0.20 mL/day was administered orally by gavage to each mouse. For the 
growth improvement and better survival of B. longum subsp. longum FA1 and B. breve 
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M4A, the strains were cultured in 10% reconstituted skim milk media. The media were 
supplemented with different concentrations of two carbohydrates and yeast extract. 
Skimmed milk was supplemented with 0.3% yeast extract and 3% oligofructose for B. 
longum subsp. longum FA1 or 3% glucose for B. breve M4A. 
Table 1: Composition of experimental diets 
Diet composition 
(g/kg) 
Control diet 
(10%kcal from fat) 
High fat diet 
(70%kcal from fat) 
Crude Protein (Casein) 210.89 210.36 
Crude Fat * 38.80 436.14 
Crude Fiber (Cellulose)  40.26 33.15 
Crude Ash 46.96 48.96 
Monosaccharide 26.24 68.95 
Disaccharide 130.56 66.24 
Polysaccharide (Starch) 413.40 102.45 
Choline chloride 1.01 1.00 
Vitamin premix** 0.563 0.551 
Minerals premix**  36.01 31.32 
Moisture  80.36 30.09 
Energy (kcal/kg) 3,493.98 5,613.25 
* Butter, lard and unsaturated fatty acids (Oleic acid and Linoleic acid).  
**According to the standard composition for mice feed prepared by Altromin-Germany; 
http://www.altromin.de 
 
The fermented milk cultures administered to the HFD-FA1 and HFD-M4A groups 
contained 2.9×106 CFU/day of B. longum subsp. longum FA1 and 4.1×106 CFU/day of 
B. breve M4A, respectively. For establishing an equal stress, the HFD group was orally 
(by gavage) given the same dose of skimmed milk supplemented with 0.3% yeast 
extract and 3% glucose as the intervention groups. The food intake and the mice were 
both weighed weekly using a balance (Ohaus-Explorer Pro, Switzerland). The different 
groups of animals were fed as follows:  
1. The HFD group was fed a high-fat diet. 
2. The HFD-FA1 group was fed a high-fat diet and received B. longum subsp. longum 
FA1. 
3. The HFD-M4A group was fed a high-fat diet and received B. breve M4A. 
 At the end of the study, mice were euthanized under CO2 with humane endpoints.      
     
Food intake (FI), ‘the amount of food ingested by the animals in each group’ was 
calculated. Mice were moved to clean cages and the amount of food given to them was 
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weighed. Any food remaining in the previous cage was also weighed. These 
measurements were repeated weekly, and the FI (g/day per mouse) was calculated 
using the following equation according to (Feige et al. 2008): 
FI (g/day per mouse) = (W0 − Wed) / (nd × nm), 
W0 = weight (g) of the food provided, 
Wed = weight (g) of the food remaining in the cage at the end of the feeding period,  
nd = number of days over which FI was calculated, 
and nm = number of mice per cage. 
Serum samples were stored at −80°C until used. The total serum cholesterol, 
triglyceride and alanine aminotransferase (ALT) levels were measured using a Reflotron 
analyser (Roche Basel, Switzerland) following the manufacturer’s instructions. The 
Reflotron analyser was calibrated using calibrating strip and then 32-μL serum samples 
were added to strips for measurement of ALT, triglycerides and cholesterol. The 
Reflotron instrument automatically detected the measurement type using magnetic tape 
fixed on the strips. 
2.9. Pathology   
Lipid extraction and sample preparation  
Approximately 50 mg of liver tissue was weighed and transferred into a 2 ml Eppendorf 
cup tube (Chem solute & VWR, Germany) that contained 500 µl of n-hexane: 
isopropanol (3:2, v/v; (Hara et al. 1978) .The  liver tissue was disrupted with a bead mill 
(Tissuelyser II - Qiagen, Hilden, Germany) for 3 min at 20 Hz in a mixer mill. The tissues 
were homogenized by shaking (Eppendorf mixer, type 5432, Wesseling, Germany) for 
30 min. The homogenate sample tubes were centrifuged at 1000×g (Concentrator plus-
Eppendorf, Germany) for 10 min at 4°C. The supernatant was transferred to a new tube, 
and the bottom residue was discarded. The supernatant can be stored in a tight cup 
tube at -20 °C (Rodríguez-Sureda et al. 2005). Aliquots of the lipid extracts were dried 
and the lipids solubilized using a 1:1-mixture of chloroform and Triton X-100 (De Hoff et 
al. 1978). 
Triglyceride and cholesterol measurement   
Triglycerides and cholesterol of the liver were determined with colorimetric quantification 
Fluitest® kits (Analyticon- Biotechnologies AG, Germany) measured the absorbency at 
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546 nm (Cary 50BIO-Varian, Darmstadt, Germany). The measurements were performed 
with test kits TG: triglycerin (method: GPO-PAP, No. 5741) and cholesterol (method: 
CHOD-PAP, No. 4241) for triglyceride and cholesterol, respectively.  
Bacterial count of the large intestine content 
The cecum and a portion of the adjacent colon tissue of each mouse were removed and 
placed in capped sterile tubes. After transfer to a laminar flow cabinet, 1 gram of each 
sample contents was transferred to a tube with 9 mL of Ringer (Sigma-Aldrich) solution 
(1/4 power) and homogenized by vortexing for 1 minute. Eight to nine fold serial dilutions 
of each sample were performed which were plated with selective mupirocin 100 mg/L 
MRS agar medium for bifidobacteria count and the MRS agar medium was used for 
lactic acid bacteria count. Both media were incubated anaerobically at 37°C for 72h in 
triplicate. The numbers of CFU were expressed as log CFU/g. 
Histology of liver tissues 
Tissues were analysed histologically to assess the development of obesity and the 
morphological structures of the fatty liver. Liver tissues were fixed in paraformaldehyde 
(PFA), dehydrated in ethanol, cleared using xylene and then embedded in paraffin 
(ParaplastPlus-Sigma, Germany). The tissues in paraffin blocks were then sectioned 
and stained using haematoxylin (Roth-Karlsruhe, Germany) and eosin (Thermo Electron 
Corporation, USA).  
Haematoxylin and eosin staining 
Tissue slides were rehydrated with water then stained using haematoxylin and eosin 
which stained the nuclei dark blue and the cytoplasm pink, respectively. This allows cell 
types to be differentiated and fat content and cell size to be determined.  
Fixation and dehydration  
Fixation in para-formaldehyde is used to protect the tissues against bacteria and 
enzymatic degradation. The conserved structure of the tissue was used for fatty liver 
examination. 
Phosphate buffered saline PBS (1x) preparation 
 35 
 
PBS buffer saline solution were prepared from 8.0g NaCl, 0.2g KCl, 1.42g Na2HPO4 (Or 
Na2HPO4. 2H2O), 0.27g KH2PO4, and dissolved in 950 ml distilled water at pH value 7.4. 
The volume was completed to 1 liter and the pH checked again.  
Paraformaldehyde preparation 
Almost 1g of PFA was dissolved in 100ml PBS (1x) under warming conditions with 1N 
NaOH (about 5 drops). It was important the pH value doesn’t increase above 8. After 
liver samples were weighted and taken out, the liver tissues were cut off 
5mm×5mm×5mm piece. Probes were fixed overnight in fixation cassette in 1% 
PFA/PBS. Next day samples were washed extensively and embed in paraffin.  
Dehydration of tissue 
Liver tissue was placed in different solutions of the Enclosed Tissue Processor (Leica 
ASP 300S, Germany) of ethanol, xylene and paraffin (table 2). The tissues remained in 
xylene until they became transparent. Liver tissue was transferred into plastic 
embedding cassettes. Tissue samples were placed in a steel tray, partly bottom filled 
with liquid paraffin then immersed in a paraffin bath (Leica RM 2165, Germany). The 
cassette was placed on top of the steel tray and was completely filled with liquid paraffin.  
Table 2 : Dehydration of the liver tissues 
Step  Solution  Time  
1  70% ethanol  30 minutes  
2  96% ethanol  1-2 hours  
3  96% ethanol  over night  
4  100% ethanol  30 minutes  
5  100% ethanol  until end of day  
6  100% ethanol  over night  
7  100% ethanol + a drop of eosin  1 hour  
8  50/50 xylene and 100% ethanol  30 minutes  
9  xylene  1-5 minutes  
10  liquid paraffin  3 hours  
11  liquid paraffin  3 hours  
12  solid paraffin  over night  
The paraffin was solidified (Leica EG 1150 C, Germany) at -18°C for one hour. 
Sectioning was performed with a microtome (Leica RM 2165, Germany). Sections of the 
paraffin embedded tissue were cut off into 3 μm using a microtome blade (Feather A35, 
Japan) and transferred to a water bath at 40 °C. 
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The warm water made the sections stretch out before they were transferred to glass 
slides (Super-Frost Ultra plus, Germany). The slides were dried at 30°C (Memmert, 
Germany) and then placed in a box for subsequent staining (Lynch et al. 1969).  
Staining with hematoxylin and eosin  
Slides of tissues (table 3) were stained in order to examine the cells under a 
microscope. The dyeing reaction of Hematoxylin and Eosin on the nuclei and cytoplasm, 
respectively, made it possible to differentiate cell types and determine fat and cell size. 
The tissues were rehydrated with water before staining. After staining with both 
colorants, the tissues were dehydrated with ethanol and xylene before they were sealed 
with mounting medium. The tissue slides were put into racks which were placed in a 
number of glass baths. These glass baths were filled with the liquids. After the staining 
process, the slides were mounted with the Pertex (Merck, Germany) and a thin glass 
slide was placed on top. 
Table 3 : Dehydration of tissue before hematoxylin staining for paraffin sections 
Incubation 
time (min)   
Reagent Note 
 40-60 60°C in an incubator 
10 xylene   
10 xylene   
5 xylene   
5 Ethanol abs. 99,6%   
5 Ethanol abs. 99,6%   
5 Ethanol abs. 96%   
2 Ethanol abs. 70%   
5 Tap water   
2 Hämalaun- solution ready for use after Mayer 
5 tap water   
15'' Eosin-Lösung ready for use of water 
soluble Eosin 
< 1' tap water  
2 Ethanol 96%   
5 Isopropanol   
5 Isopropanol   
5 xylene   
5 xylene   
5 xylene   
 Cover sliding with Pertex   
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Oil Red O Staining 
Liver tissues sized 5 × 5 × 5 mm were harvested from frozen cryoembedded tissues and 
then frosted in cryomedium in embedding cryocassettes on dry ice. The frosted samples 
were stored at −80°C until analysis. The remaining liver samples were snap-frozen in 
liquid nitrogen. 
Oil Red O staining was used to detect lipid accumulation in liver tissues. To produce the 
stock solution, 0.5 g of Oil Red O was dissolved in 100 mL isopropanol with gentle 
heating in a water bath. Fresh stain was prepared for each experiment. 
Ten-micrometre sections were cut and then air-dried. Slides were fixed in 10% formalin or 
4% paraformaldehyde and washed briefly with running tap water for 1–10 min.  
Mayer’s Hematoxylin Solution 
 The Mayer’s Hematoxylin solution was purchased from Carl Roth-76185 Karlsruhe, 
Germany.   
Oil Red O Stain (0.5%) solution 
Oil red O powder……………0.5 g 
60% isopropanol…………100.0 ml 
A small amount of propylene glycol was added to the oil red O and mixed well. The 
remainder of the propylene glycol was gradually added and periodically stirring. The 
solution was gently heated until the solution it reaches 95°C. (The solution was avoided 
to go over 100°C.) Stir while heating. Filter through coarse filter paper while still warm. 
Allowed to stand overnight at room temperature. Filter again before use. 
60% Isopropanol Solution 
Isopropanol……………60.0 ml 
Distilled water…………40.0 ml 
Note: The oil red O solution and 2 Coplin jars of 60% isopropanol glycol were stored an 
oven at 60°. They were then rinsed with 60% isopropanol and stained with freshly 
prepared Oil Red O working solution for 15 min. After rinsing briefly with 60% isopropanol, 
the nuclei were stained lightly with alum haematoxylin. Additionally, the slides were rinsed 
with distilled water, and mounted in Dako® fluorescent mounting medium (Dako, USA) and 
covered with coverslips (Koopman et al., 2001; Speranza and Fail, 2005). 
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Staining Procedure 
 Dip briefly in distilled water. 
 Dip slides in undiluted isopropanol. 
 Stain in oil red O solution for 1 minute at 60°C. 
 Differentiate by dipping twice in each of 2 changes of 60% isopropanol at 60°C. 
 Rinse in 2 changes of distilled 
 Counterstain in Mayer’s hematoxylin for 30 seconds. Be sure to filter hematoxylin 
prior to use if not filtered daily. 
 Rinse in distilled water. Do not use acid alcohol. Do not dehydrate through 
alcohol. 
 Mount in an aqueous mounting medium. 
 Results: Fat……………Intense red, nuclei ………………Blue 
The staining of the lipid droplets were visualized using a light microscope (LEITZ DMRB-
Leica, Germany) at 100X magnification. Pictures were taken with a digital camera (MXA 
5400-Nikon) and setting it on 1.6 second, shutters F4.6, brightness light 8, visibility 
(50%:50%). Lipid droplets size in microscopy images were determined by Image J 
software program (2 x 2.1.7.4). The photos analysed with binary setting and the area 
calculated. Dirty or air bubbled photos were avoided.  
2.10. Statistical analyses 
All experiments were repeated three (two for doubling time) times. The analyses were 
performed in dublicate. Statistical analyses were performed using SPSS version 
22.0.0.1 (IBM software, USA). Analyses of variance (ANOVA) was used for multiple 
comparisons for doubling time, and p < 0.05 and p < 0.01 were considered statistically 
significant and highly significant, respectively. The post hoc least significant difference 
(LSD) test was chosen for homogenous variances. To assess the relationship between 
yeast extract, oligofructose, glucose and the doubling time we used three factorial 
Analyses of variance ANOVA making use of the mixed procedure in SPSS program to 
account for heterogeneity of variances in an unbalanced design. 
The mediation analysis of indirect effects media supplemented with yeast extract, 
glucose and oligofructose affected on count number and acid production. The indirect 
influence of the skimmed milk media affected on pH value in such nonlinear model. The 
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relationship were evaluated between Medium (yeast extract, oligofructose and glucose) 
on pH via count number as a mediator using multiple, nonlinear regression models. 
Multiple Regression analyses of dependent factors of pH value and count number. The 
factorial design of our analysis was nonlinear relationship between independent and 
dependent variables.   
(1) y = a + b1*x1 + b2*x1² + b3*x2 + e 
(2) y = a + b1*x1 + b2*x1² + e 
With y = dependent variable (here: pH), a = constant, e = error term, b1 ... b3 = 
regression coefficients, x1 ... x2 = independent variables (glucose and oligofructose and 
count number), x1² = x1 squared (power term for nonlinear part of the model). The 
unbalanced present or not some ingredient and more or less concentration of glucose, 
and oligofructose with heterogeneity of variance, therefore, we cannot run p value and 
trust with it. Another ANOVA was run to its hidden and mix procedure accounting for the 
heterogeneity of ANOVA and correcting the p value.  
All experiments were repeated three times independently with randomized designs. The 
analyses were performed in triplicate. Statistical analyses were performed using SPSS 
version 22.0.0.1 (IBM software, USA). Comparison of the bacterial number was made 
after logarithmic transformation. Pairwise of the single comparisons was used (each 
treated group to the HFD group), and p < 0.05 and p < 0.01 were considered statistically 
significant and highly significant, respectively. The post hoc LSD test was chosen for 
homogenous variances; in cases with heterogeneity of variances, Tamhane’s T2 test is 
performed. For data sets with outliers, medians were analysed instead of means and the 
median test was used. 
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3. Results 
3.1. Media selectivity 
Typical morphological cell shapes of Bifidobacterium spp. were distinct from non-
Bifidobacterium spp. Figure (2) shows bacteria from infant feces under contrast phase 
microscope in MRS agar media. The supplemented media with different mupirocin 
concentrations 30, 40, and 80 (mg/L) respectively, showed different levels of visual 
differentiation or selectivity of presumptive Bifidobacterium spp. from non-bifidobacteria. 
Figure (2A) showed the typical B. infantis shape growth in the mupirocen 30 (mg/L) from 
pure culture.  
 
Figure 2: Bifidobacteria and non-bifidobacteria from infant feces in contrast phase microscopy 
(100x) after growth on MRS agar media. (A): Typical cell shape of B. infantis (DSMZ no. 20088); (B): 
Low selectivity (30 mg/L mupirocin); (C): Selective (40 mg/L mupirocin) and (D): High selectivity 
(80 mg/L mupirocin). 
The mupirocin concentration 30 (mg/L) in figure (2B) showed inconsistent selectivity 
against non-bifidobacteria species. The level 40 mg/l of mupirocin figure (2C) was 
considered a visual differentiation of presumptive Bifidobacterium spp. from non-
bifidobacteria which enhanced at this level of mupirocin. While figure (2D) supplemented 
with 80 (mg/L) mupirocin resulted in a higher selectivity and readily distinguishable 
presumptive bifidobacteria cell morphology. 
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4.2. Bacterial counts 
Bacterial growths from infant feces were determined from colony-forming unit counts. 
Figure (3) showed white rounded colony. These colonies were presumptive for 
bifidobacteria in the highest level of mupirocin MRS agar media.  
 
Figure 3: Mupirocin (80 mg/L) MRS agar plates inoculated with infant feces, incubated 
anaerobically at 37 ˚C for 72 h. Colony morphology examples indicating typical Biﬁdobacterium 
spp. 
Cell numbers of CFUs have been determined from feces of infants. In figure (4) the CFU 
of a newborn baby (one day old) was non-detected.  
 
Figure 4: White colonies forming units of Bifidobacteria growing on MRS agar media with 
mupirocin (80 mg/L) from feces of breast fed infants at different ages. 
 
From a two day old, a CFU of 5.57 log /g has been detected whereas after an age of 
three and four weeks 3.48, 3.54, 3.89 and 4.77 CFU log/g has been obtained, 
respectively.  
The CFUs of 6.84 and 7.56 CFU log/g were determined in feces of 10 weeks old babies. 
The after four and ten months the CFU remained similar 8.47, 8.79 and 7.93 log CFU/g, 
respectively.  It has been reported earlier that the number of bifidobacteria increased 
with age of the baby (Roger et al., 2010; Serafini et al., 2011). 
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3.2. Identification of Bifidobacteria isolates 
Three selected bifidobacteria isolates have been identified at the genus and species 
level. First, the gene for 16S rRNA was amplified by PCR techniques using specific 
primers. Figure (5) showed the amplified nucleotide sequences which were run on a 1% 
agarose gel electrophoresis and the amplified DNAs appeared in the region 1500 bp. 
The strains showed high level of phylogenetic similarity to the genus bifidobacterium 
where they were affiliated with a high similarity of 99.8% to B. breve M4A and a 100% 
sequence identity to B. longum subps. longum FA1. The Phylogenic method from NCBI 
site was queried (figure 6). The accession numbers of the specific species of 
bifidobacteria were selected. The construction likelihood phylogeny tree was chosen and 
aligned using the MEGA 5.10 Program 
 
Figure 5: Agarose-gel (1%) electrophoresis of PCR products. Lambda DNA/ EcoRI+ Hind III was 
used as marker (M). E. coli and water were used as positive and negative control, respectively. The 
(FA1) and (M4A) bands represented the amplified nucleotide sequences for B. longum subps. 
longum, and B. Breve, respectively. 
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Figure 6: Phylogenetic tree based on 16S rRNA gene sequences, showing the affiliation of the 
isolates of the present study B. longum subsp. longum FA1 and B. breve M4A with 
Bifidobacterium species. 
3.3. Biochemical tests and further characterization  
Biochemical assays testing the organism’s ability to utilize various saccharides were 
conducted because different species (strains) ferment different substrates and produce 
different enzymes epend on Bifidobacteria species (Holdeman et al. 1977). The 
biochemical tests were used to confirm the identification of B. longum subspecies. The 
carbohydrate fermentation patterns for B. longum subsp. longum are shown in Table 4. 
EF178674, Streptomyces 
azureus AY174108, Bifidobacterium 
psychraerophilum AP009256, Bifidobacterium 
adolescentis FJ611793, Bifidobacterium 
stercoris D86197, Bifidobacterium 
ruminantium D86182, Bifidobacterium 
angulatum D86192, Bifidobacterium 
merycicum AF432082, Bifidobacterium 
catenulatum D86187, Bifidobacterium 
pseudocatenulatum D86183, Bifidobacterium 
dentium D86185, Bifidobacterium animalis subsp. 
animalis AB050136, Bifidobacterium animalis subsp. 
lactis D86186, Bifidobacterium 
choerinum D86194, Bifidobacterium pseudolongum subsp. 
globosum D86195, Bifidobacterium pseudolongum subsp. 
pseudolongum D86193, Bifidobacterium 
magnum D86189, Bifidobacterium 
gallicum M58739, Bifidobacterium longum subsp. 
longum 
M58743, Bifidobacterium longum subsp. suis 
ARB_1C7193E, FAI_full 
D86184, Bifidobacterium longum subsp. 
infantis AB006658, Bifidobacterium 
breve ARB_E3C4E8AF, M4A_full 
ARB_74EDD91F, 
N4AM_short ARB_D0A36F4C, 
FBIM_short ARB_BCE3DFD7, FAIM_short 
D89378, Bifidobacterium 
subtile D86191, Bifidobacterium 
gallinarum D89328, Bifidobacterium 
saeculare D86196, Bifidobacterium 
pullorum AY148470, Bifidobacterium thermacidophilum subsp. 
porcinum AB016246, Bifidobacterium thermacidophilum subsp. 
thermacidophilum D86190, Bifidobacterium 
boum AB241106, Bifidobacterium 
tsurumiense U25952, B fidobacterium 
bifidum AJ307005, Bifidobacterium 
scardovii M58733, Bifidobacterium 
coryneforme D86188, Bifidobacterium 
indicum EF187235, Bifidobacterium 
asteroides M58741, Bifidobacterium 
minimum AB433856, Bifidobacterium 
mongoliense 
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They depend on their specific characteristics which have been identified by species-
specific PCR with some similarities among B. longum sub-species (Palframan et al. 
2003; Sakata et al. 2002).    
Table 4: Carbohydrates fermentation by isolates of Bifidobacterium longum 
 
 
3.4. Lyophilisation procedure  
The CFU of the MRS broth culture before lyophilisation for B. longum subsp. longum 
FA1 and B. breve M4A was 6.77 and 6.87 log CFU/mL, respectively (Table 5). The 
survival rates were 71.8% and 81.5% for B. longum subsp. longum FA1 and B. breve 
M4A, respectively. The number of viable cell counts after six months storage were 5.06 
and 6.84 log CFU/mL for B. longum subsp. longum FA1 and B. breve M4A, respectively. 
The survival rates after six months storage were 74.7% and 99.6% for B. longum subsp. 
longum FA1 and B. breve M4A, respectively. 
 
Table 5: Viability of B. longum subps. longum FA1 and B. breve M4A before and after 
lyophilisation (log CFU/mL) with their survival rate. 
Culture Viability 
before 
lyophilisation*  
Viability 
after 
lyophilisation   
Survival 
rate before  
Storage % 
Viability  
after 6 
months 
Survival 
rate after 
storage % 
B. longum subps. 
longum FA1 
6.77 4.86 71.78 5.06 74.74 
B. breve M4A 6.87 5.60 81.51 6.84 99.6 
   * Lyophilisation at pH=4  
 
3.5. pH-reduction  
Figure 7 depicts continuous reduction of pH during a 48 h incubation period for B. breve 
M4A. The pH in the control was 4.71, whereas figure 8 shows that with all treatments pH 
decreased to less than 4. For B. longum subsp. longum FA1, the pH in the control was 
5.03, whereas the pH with all treatments decreased to 4. 
 
Isolate Control Glucose L-Arabinose Ribose 
B. longum subsp. Longum FA1 - + + - 
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Figure 7: Altered pH values of B. breve M4A after 48 h of incubation at 37˚C M4A in various 
supplemented milk media SK = skim milk media containing variations concentrations of YE = 
yeast extract, G = glucose, and Olig = oligofructose. Each histogram bar represents the mean 
value of duplicate. 
 
Figure 8: Altered pH values of B. longum subsp. longum (FA1) after 48 h of incubation at 37˚C M4A 
in various supplemented milk media SK = skim milk media containing variations concentrations of 
YE = yeast extract, G = glucose, and Olig = oligofructose. Each histogram bar represents the mean 
value of duplicate. 
3.6. Use of supplemented media  
Doubling time was used as a measure of the effects of yeast extract, glucose, and 
oligofructose concentrations on growth density of bifidobacteria. The enhancement of 
the growth rates of B. longum subsp. longum FA1 and B. breve M4A were evidenced by 
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significantly reduced doubling times compared to the controls. As depicted in figure (9) 
there was a dose-dependent growth improvement of B. longum subsp. longum FA1 
secondary to 0.6% yeast extract and 0.3% yeast extract supplemented with either 
glucose or oligofructose at 1%, 2%, and 3%. Among the carbohydrate sources tested, 
treatment with skim milk + 0.3% yeast extract + 3% oligofructose was the most effective, 
resulting in a significantly reduced doubling time. All treatments involving 
supplementation with oligofructose resulted in a significantly decreased doubling time 
compared with treatments involved supplementation with glucose and yeast extract.  
Figure (10) shows the enhancement of the growth of B. breve M4A by various 
supplements. Among the carbohydrate sources tested, skim milk + 0.3% yeast extract + 
3% glucose provided the shortest mean doubling time and oligofructose resulted in a 
significantly reduced doubling time compared with treatment involving yeast extract as 
the sole supplement and skim milk + 0.3% yeast extract + 1% glucose. 
 
 
 
 
 
 
 
 
 
 
Figure 9: Doubling time of B. longum subps. longum FA1 in SK=skim milk media containing 
different concentrations of YE = yeast extract, G = glucose, and Olig = oligofructose. Different 
letters indicates’ highly significant (p<0.01) differences among treatment means (mean ±SD). 
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Figure 10: Doubling time of B. breve M4A in SK = skim milk media containing different 
concentrations of YE = yeast extract, G = glucose, and Olig = oligofructose. Different letters 
indicates’ highly significant (p<0.01) differences among treatment means (mean ±SD). 
 
3.7. Viability of cells  
The highest viable cell number achieved by B. longum subsp. longum FA1 was 8.21 log 
CFU/ mL with the skim milk + 0.3% yeast extract + 1% oligofructose treatment and the 
lowest viable cell number was 7.70 log CFU/ mL for the skim milk (Control), followed by 
8.11, 8.04, 8.03, 8.01, 7.96, 7.95 and 7.86 log CFU/ mL for the skim milk + 0.3% yeast 
extract + 3% glucose; skim milk + 0.3% yeast extract + 2% oligofructose; skim milk + 
0.3% yeast extract + 3% oligofructose; skim milk + 0.6% yeast extract; skim milk + 0.3% 
yeast extract + 1% glucose; skim milk + 0.3% yeast extract + 2% glucose and skim milk 
+ 0.3% yeast extract, treatments, respectively (Figure 11). The highest viable cell 
number achieved by B. breve M4A was 8.46 (log CFU/ mL) in the skim milk + 0.3% 
yeast extract + 2% oligofructose treatment and the lowest viable cell number was 8.17 
for the skim milk (Control), followed by 8.43, 8.42, 8.42, 8.41, 8.40, 8.33 and 8.30 (log 
CFU/ mL) for the skim milk + 0.3% yeast extract + 3% oligofructose; skim milk + 0.6% 
yeast extract; skim milk + 0.3% yeast extract + 2% glucose; skim milk + 0.3% yeast 
extract + 1% oligofructose; skim milk + 0.3% yeast extract + 3% glucose; skim milk + 
0.3% yeast extract and skim milk + 0.3% yeast extract + 1% glucose treatments, 
respectively.  
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Figure 11: Treatments with supplemented skim-milk media resulted in significant increases (p 
<0.01) in viable cell numbers of both B. breve M4A and B. longum subsp. longum FA1 compared 
with skim-milk medium alone (control). SK=Skim milk; YE=Yeast extract; G= glucose; Olig= 
Oligofructose (mean ±SD). 
 
3.8. Surface response to the supplemented media  
The response surface plots in figure (12) showed the relationship between the count 
number (log CFU/mL) of B. longum subsp. longum FA1 and different media. The 
maximum count number 8.21  and 7.70 (log CFU/mL) of B. longum subsp. longum FA1 
were obtained from 3% glucose  followed by 1% oligofructose  supplemented medium, 
respectively.  
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Figure 12: Response surface plots for the count number (log CFU/mL) of B. longum subsp. longum 
FA1 with different media. The response surface factors are; (a) SK+YE0.3+Olig1%, SK+YE0.3+G1% 
and SK+YE0.3% media, and the pH. (b) SK+YE0.3+Olig2%, SK+YE0.3+G2% and SK+YE0.3% media, 
and the factor the pH. (c) SK+YE0.3+Olig3%, SK+YE0.3+G3% and SK+YE0.3% media, and the 
factor the pH. (d) SK, SK+YE0.3% and SK+YE0.6% media. (SK; Skimmed milk, YE; yeast extract, G; 
glucose, Olig; oligofructose). 
 
The highest acid production and the highest count number of the surface plot shown in 
figure (12a) whereas the lowest levels of acid production and count number of the 
surface plot illustrated in figure 12 (b, c & d) were the media with lower carbohydrate 
concentration and without carbohydrates. Figure (13) showed response surface plot 
representing an optimized count number 8.46 and 8.43 (log CFU/mL) of B. breve M4A in 
figure (13a) attributed to the oligofructose 3% and glucose 3% supplemented media, 
respectively. The supplemented skimmed milk media with 1% and 2% of carbohydrates 
showed in figure 13 (b, c & d) had been less improvement of the pH values as well as 
count number.   
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Figure 13: Response surface plots for the count number (log CFU/mL) of B. breve M4A with 
different media. The response surface factors are; (a) SK+YE0.3+Olig1%, SK+YE0.3+G1% and 
SK+YE0.3% media, and the factor the pH. (b) SK+YE0.3+Olig2%, SK+YE0.3+G2% and SK+YE0.3% 
media, and the pH. (c) SK+YE0.3+Olig3%, SK+YE0.3+G3% and SK+YE0.3% media, and the factor 
the pH. (d) SK, SK+YE0.3% and SK+YE0.6% media. (SK; Skimmed milk, YE; yeast extract, G; 
glucose, Olig; oligofructose). 
 
3.9. Food intake 
The total food consumption of seven weeks was 266.9, 198.4 and 165.1 g per mouse in 
the HFD, HFD-FA1 and HFD-M4A groups, respectively (Figure 14). The consumed diet 
of HFD-FA1 and HFD-M4A groups was decreased highly significant (p < 0.01) in week 4 
and decreased significant (p < 0.01) of HFD-M4A group in week 3 in comparison with 
HFD group. Nevertheless, the increase in total food intake in the HFD group was not 
significantly higher than the HFD-FA1 and HFD-M4A groups.  
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Figure 14: Total diet consumption of mice treatments after 6 weeks of administration of B. breve 
M4A  and B. longum subsp. longum FA1 for HFD-M4A group and HFD-FA1 group, respectively 
(mean ±SD; * Significant at p<0.05; ** Significant at p<0.01). 
 
 
3.10. Body weight and weight gain 
A significant difference (p<0.01) in body weight was already observed one week after 
the start of the supplementation phase between HFD-M4A group and HFD group, with a 
decreased weight gain in HFD-M4A group (figure 15).  
 
Figure 15: Body weight development of the three treatment groups. One group received high-fat 
diet only, one received HFD and B. breve M4A (4.1×106 CFU/day), one received B. longum subsp. 
longum FA1 (2.9×106 CFU/day). From time 0 to 1, all groups were on control diet. HFD started from 
time point 1. Additional supplementation started at time point 2 and had a duration of six weeks. 
Data are expressed as mean ±SE; * Significant at (p<0.05); ** Significant at (p<0.01). 
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The administration of B. breve M4A and B. longum subsp. longum FA1 decreased 
weight gain significantly (p < 0.01) in the HFD-M4A and HFD-FA1 groups compared with 
the HFD group that was 2.09, 3.44 and 5.54 g per mouse, respectively (Figure 16).  
 
Figure 16: Weight gain of mice after 6 weeks of administration of B. breve M4A and B. longum 
subsp. longum FA1 for HFD-M4A group and HFD-FA1 group, respectively. (mean ±SD; * Significant 
at p<0.05). 
3.11. Bacterial counts  
The number of lactic acid bacteria in the intestines of the HFD-FA1 and HFD-M4A 
groups were 9.52 and 9.62 log CFU/g, respectively, which was increased highly 
significant (p < 0.01) in comparison with (6.68 log CFU/g) the HFD group (Figure 17).  
 
Figure 17: Count number of lactic acid bacteria from intestinal contents of mice treatments after 
administration of B. breve M4A and B. longum subsp. longum FA1 for HFD-M4A group and HFD-
FA1 group, respectively. (mean ±SE; ** Significant at p<0.01). 
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The number of bifidobacteria increased highly significant (p < 0.01) in the HFD-M4A and 
HFD-FA1 groups was 8.80 and 8.76 log CFU/g, respectively, compared to 6.57 log 
CFU/g in the HFD group (Figure 18). 
Figure 18: Count number of bifidobacteria from intestinal contents of mice treatments after 
administration of B. breve M4A and B. longum subsp. longum FA1 for HFD-M4A group and HFD-
FA1 group, respectively. (mean ±SE; ** Significant at p<0.01). 
 
3.12. Serum triglycerides  
Figure (19) shows that the administration of B. breve M4A in the HFD-M4A group 
decreased triglyceride levels significantly (p < 0.05) to 125.38 (mg/dL) compared with 
174.429 (mg/dL) in the HFD-group. There were no significant differences in triglycerides 
between (160.33 mg/dL) the HFD-FA1 and HFD groups. Total serum cholesterol levels 
and serum ALT enzyme levels (figure 20) were not significantly different among groups.  
 
Figure 19: Total cholesterol and triglyceride levels in serum of mice after six weeks of 
administration of B. breve M4A and B. longum subsp. longum FA1 for HFD-M4A group and HFD-
FA1 group, respectively. (mean ± SE; * Significant at p<0.05) 
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Figure 20: Serum ALT enzyme level test (mean ± SE) of HFD-M4A and HFD-FA1 groups fed high fat 
diet in combination with B. breve M4A and B. longum subsp. longum FA1, respectively compared 
with HFD group. 
3.1. Hepatic triglycerides and cholesterol  
The hepatic triglyceride content (figure 21) of the HFD-FA1 group was 12.8 mg/g and 
11.1 mg/g in the HFD group, and 9.18 mg/g in the HFD-M4A group. However, there 
were no significant differences among group means of the triglyceride level. The liver 
cholesterol level was not significantly different among groups. 
 
Figure 21: Total cholesterol and triglyceride levels in liver of mice after six weeks of administration 
of B. breve M4A and B. longum subsp. longum FA1 for HFD-M4A group and HFD-FA1 group, 
respectively. (mean ± SE). 
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3.1. Bifidobacteria and hepatic histology  
The Oil Red O-stained area was calculated to assess triglyceride accumulation in the 
liver using Image J software. The proportion of the lipid droplets area in cryosection 
images was 12.43% in the HFD group, which was significantly high (p < 0.01) compared 
with 3.40 and 2.46% in the HFD-FA1 and HFD-M4A groups, respectively (Figure 22).  
Figure 22: Calculated area (%) of Oil Red O staining photos imaging cryosections to determine 
triglyceride accumulation in liver by Image J program. A: high fat diet; B: high fat-diet+B. longum 
subsp. longum FA1; C: high-fat diet+B. Breve M4A. Photos A, Photos A, B and C were Oil Red 
stained native cryo-lices/liver. Magnif. 200x and 1000x, bars 200µm. (mean ±SE; ** Significant at 
p<0.05). 
 
Figure (23) shows images of haematoxylin and eosin-stained liver sections (100× and 
1000× magnification). The haematoxylin and eosin-stained section showed cells were 
being sized with fat content (figure 23 A). The different diets did not influence liver 
architecture or inflammatory status of the liver. The liver mass (figure 24) of mice was 
decreased significantly (p<0.01) by feeding with high fat diet in combination with B. 
 56 
 
breve M4A to 0.90 g of the HFD-M4A group in comparison to 1.11 g of the HFD group. 
Whereas, no significant difference was demonstrated between the HFD group and (1.06 
g) the HFD-FA1 group. 
 
Figure 23: Haematoxylin & eosin-stained paraffin slices of liver showing the microvascular lipid 
droplets. Magnification 100x and 1000x, bars 100μm. A: high fat diet; B: high fat-diet + B. longum 
subsp. longum FA1; C: high-fat diet + B. Breve M4A.  
 
The administration of B. longum subsp. longum FA1 and B. breve M4A to the HFD-FA1 
and HFD-M4A groups, respectively, altered liver lipid droplet accumulation compared 
with the HFD group.  
Figure 24: Liver weight of mice after feeding with high fat diet in combination with B. breve M4A of 
HFD-M4A group. (mean ± SE). **highly significant (p<0.01). 
  
 57 
 
4. Discussion 
Bifidobacteria are used as probiotics for the prevention and treatment of pathologies 
typical of newborns, such as necrotizing enterocolitis and streptococcal infections. 
Furthermore, allergic diseases, celiac disease, obesity, and neurologic diseases 
potentially presented new opportunities for probiotic applications of bifidobacteria (Di 
Gioia et al, 2014). Short chain fatty acids are the primary end products of carbohydrate 
metabolism in bifidobacteria lowering the pH and reducing the growth of undesirable 
microorganisms in the intestine, as well as to increase peristalsis pushing the gut 
contents forward and eventually helping to remove pathogens (Matsuki et al. 2013). Due 
to acetate production, B. longum subsp. longum strain JCM 1217T prevented the 
apoptosis of intestinal epithelial cells when E. coli O157 were administrated to germ-free 
mice (Fukuda et al. 2011). 
Mupirocin MRS selective media was used for isolating Bifidobacteria ssp. from breastfed 
infant’s faeces. The isolation and differentiation of bifidobacteria from other anaerobic 
bacteria can be difficult because of shared biochemical properties and habitats. The 
MRS mupirocin-based media appeared to suit best for enumeration of bifidobacteria in 
selective media (Simpson et al. 2003). Fortunately, bifidobacteria resist inhibition of the 
antibiotic mupirocin which may serve as a simple criterion distinguishing Bifidobacterium 
spp. from others (Rada 1997). With the lowest concentration of mupirocin it was found 
that bifidobacteria were outgrown by other bacteria while the concentration of 40 (mg/L) 
mupirocin suppressed the growth of most other bacteria (Figure 2). Previous studies 
have found that the addition of 25 (mg/L) mupirocin to transoligosaccharide propionate 
(TOS) agar medium resulted in inconsistent selectivity against non-bifidobacteria 
species of poultry caeca origin. The addition of 50 mg/l mupirocin to TOS makes it an 
effective selective medium for the isolation and enumeration of Biﬁdobacterium spp. 
from chicken faeca samples (Thitaram et al. 2005). As Figure 6 (d) shows, in this study 
the highest concentration of mupirocin (80 mg/L) gave the highest selectivity for the 
growth of bifidobacteria. While the addition of mupirocin at levels as high as 100 (mg/L) 
suppressed the growth of lactic acid bacteria, it still permitted the growth of 
Bifidobacterium spp. on broth pure cultures (Rada et al. 2000). Such findings indicate 
that most, if not all, bifidobacteria exhibit stable resistance to mupirocin at moderate-to-
high levels 1,800–2,000(µg/ml) respectively (Serafini et al. 2011). 
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For this study numbers of colony-forming units (CFUs) have been determined from 
faeces of breast-fed infants. CFU of bacteria from a newborn (one day old) were non-
detectable because the gastrointestinal tract is sterile at birth (Heavey et al. 1999) and 
becomes colonized by different microorganisms soon after birth (Mitsuoka 1996). 
Bifidobacteria are normally considered the most prevalent organism in the infant’s gut 
(Franck 2007). In addition, Enterobacteria and Bifidobacteria represent early colonizers 
in breast-fed infants (Mountzouris et al. 2002).  
Table 1 illustrates that the CFUs increased with the infants growing older, by which time 
the commensal bacteria start to develop a normal intestinal microbiota. The 
Biﬁdobacteria almost dominate the gut of breast-fed infants (Palmer et al. 2007; Saccaro 
et al. 2011).  
The results presented in Figure 3 show a significant increase in bifidobacterial 
colonization in the infant with aging. This is because of the ingestion of biﬁdogenic 
factors in breastmilk that selectively stimulate the growth of Biﬁdobacteria (Collins et al. 
1999; Tuohy et al. 2003). The highest count described in four-month-old infants were 
8.47 and 8.79 CFUs while the count at 10 months was reduced to 7.93 CFUs because 
of the development of an ecosystem that resembles the adult profile (Mackie et al. 
1999). This change is caused by the change of diet, weaning from breastmilk, 
physiological changes in the growing infant and gastrointestinal tract maturation 
(Hopkins et al. 2005). 
Identification based on phenotypic traits does not always provide clear-cut results, 
therefore, detection of Bifidobacteria was achieved using PCR amplification and 
sequence analysis of the 16S rRNA gene (Figure 3). Identification based on the PCR 
technique was rapid and accurate for B. longum subsp. longum FA1 and B. breve M4A 
the same as those previously found in breastfed infants. B. breve was the most 
frequently detected species, followed by B. infantis, B. longum and B. bifidum when 
species-specific primers for bifidobacteria identification were used (Matsuki et al. 2003). 
B. longum subsp. longum FA1 was identified among different subspecies by 
carbohydrate fermentation test. A previous study had found that a Bifidobacterium 
longum strain had a higher survival rate when incubated in artificial gastric juice at pH 
3.0 for 1.5 to two hours (Xiao et al. 2003). 
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In the present study, two strains of bifidobacteria were used because of their origin from 
the human microbiota of breastfed infants. Since several observations have been 
reported with B. longum and B. breve both strains were studied. The isolates were 
chosen for their higher viability as recommended for probiotic microorganisms (Fukuda 
et al. 2011; Vitali et al. 2007). 
The viability of bifidobacteria in conventional media is limited. For long-term 
preservation, lyophilisation is the classical way of conservation and was also used in 
animal experiments (Heckly 1985). The detection of viable cell counts of B. breve M4A 
and B. longum subsp. longum FA1 following lyophilisation and conservation for six 
months suggested acceptable survival rates. Skim-milk fermentation increased the 
potential for acid production and decreased the doubling time in the presence of yeast 
extract, glucose, and oligofructose. Skim-milk media supplemented with yeast extract 
and glucose or oligofructose were effective in improving the growth of B. breve M4A and 
B. longum subsp. longum FA1, depending on the carbohydrate concentration and 
Bifidobacterium strain used. Bărăscu and coworkers   monitored the growth rate of 
bifidobacteria in milk supplemented with yeast extract after 24 hours of incubation time. 
The number of cells in the presence of 0.1, 0.2, 0.3, and 0.4% yeast extract increased 
stepwise as compared to the cells grown in basal medium. The highest CFU count of 
bifidobacteria was obtained with basal medium plus 0.4% yeast extract (32 x 108 
CFU/cm3). This was four times higher than that with basal medium 8 x 108 CFU/cm3 
(Bărăscu et al. 2007). 
Various studies have reported that the viability of bifidobacteria is often low in fermented 
dairy products (Adhikari et al. 2000). Dairy products, particularly fermented milk, are 
considered the best vehicle for delivering bifidobacteria to humans. Milk is a nutritional 
medium for promoting the growth of bifidobacteria, amino acids and low molecular 
weight peptides are present at low concentrations in milk only. Therefore, the 
biﬁdobacteria cultures exhibit reduced growth in milk. Many approaches have been used 
to promote the development of various bifidobacteria for accelerating milk fermentation. 
The ability of organisms to grow well in milk depends on their ability to metabolize milk 
proteins and lactose, both varying considerably among different strains (Ostlie et al. 
2003). Published reports on using supplemented milk media with sugar and growth 
factors have been limited to laboratory-scale studies that were mainly used for sub-
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culturing or propagating inoculums. In addition, no justifications were given for the 
concentrations used. Moreover, the formulations of industrial media products are rarely 
revealed because of the company’s competitive advantage. Regulatory authorities 
worldwide are seeking assurance that probiotic products could deliver viable starter 
organisms in sufficient numbers to the intestine in order to provide a benefit to 
consumers (Stephenei et al. 2007). 
Different levels of supplemented skimmed-milk media were studied for the growth of 
bifidobacteria and their acid production. The mediation analysis of skimmed-milk media 
supplemented with yeast extract, glucose and oligofructose showed an influence on the 
cell count and pH. The relationship was evaluated using supplemented media at 
different pH-levels via cell count as a mediator using multiple, nonlinear regression 
models. The design did not allow the study of interaction effects in such a model as in 
the Plakett-Burman design (Kiviharju et al. 2005). The response on surface plots 
showed that the maximum count of B. longum subsp. longum FA1 and B. breve M4A 
was achieved after 48 hours at a pH of four. For every increase in the concentration 
level of the carbohydrates, the number count increased with both B. longum subsp. 
longum FA1 and breve M4A, whereas the yeast extract levels alone exerted less 
influence on the cell count. The optimal growth of B. longum subsp. longum FA1 was 
obtained from skimmed-milk media supplemented with 3% glucose, while skimmed-milk 
media supplemented with 3% oligofructose showed a more efficiently optimized growth 
of B. breve M4A. This result indicates that the interactions between skimmed milk 
supplemented with yeast extract, and glucose or oligofructose may have a stronger 
influence on the growth rate of bifidobacteria. Consequently, the use of 3% carbohydrate 
concentration in skimmed-milk media significantly improves the pH and the cell count.   
In the animal experiment food consumption was recorded throughout the seven-week 
study period. Mice fed a high-fat diet and treated with B. breve M4A and B. longum 
subsp. longum FA1 consumed a non-significantly different amount of food than other 
groups. Administration of B. breve M4A reduced total body weight gain compared to 
HFD only. Casas et al. (2000) revealed that Lactobacillus reuteri improved the intestine’s 
ability to absorb and process nutrients and increase food conversion. Another study 
reported that Lactobacillus reuteri was the only species present at higher levels in the 
gut microbiota of obese individuals whereas levels of B. animalis and 
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Methanobrevibacter smithii were higher in non-obese subjects (Million et al. 2012). A 
high-fat diet is considered one of the environmental factors that contributes most to the 
epidemic of obesity (Peters 2003; Bray et al. 2004).  
In the current study, mice fed a high-fat diet (HFD) had an increased body weight. The 
influence of six weeks of exposure to the HFD on weight gain was a positive fat balance. 
The gut microbiota produces energy from undigested food (Cani et al. 2009). The 
administration of B. breve M4A might modulate the composition of the gut microbiota in 
the regulation of energy homeostasis. Another variable that might influence weight gain 
was observed in the HFD-FA1 and HFD-M4A groups. B. breve M4A and B. longum 
subsp. longum FA1 may lead to an altered intestinal microbiota that minimizes the 
amount of energy stored in adipose tissue, thereby, reducing weight gain. The proposed 
mechanism was that gut microbiota play an important role in energy homeostasis in the 
host’s intestine (Cani et al. 2009). Thus, weight gain was less in these two intervention 
groups. B. breve M4A and B. longum subsp. longum FA1 might reshape the balance of 
the intestinal microbiota and modulate body weight. 
Each B. breve strain may have a different capability of carbohydrate utilization as 
another study suggested. The genetic accessibility and murine colonization capacity of 
this strain makes it a valuable model for understanding bifidobacterial–host interactions 
in the gut (O’Connell Motherway et al. 2011). Maximal counts and generation times of B. 
breve, B. bifidum, B. infantis, and B. longum were not influenced by 0.5% 
fructooligosaccharides(FOS) when the organisms were grown in infant formula (Dubey 
et al. 1996), but the group did not investigate FOS-concentrations above 0.5%. 
Consistent with these findings, (Shin et al. 2000) observed significant differences in 
mean doubling times when the bifidobacteria strain was grown in the presence of 0.5% 
FOS. Through the valuable content of amino acids, the yeast extract may contribute to 
the growth stimulation of bifidobacteria and also to improved viability in dairy products 
(Bărăscu et al. 2007).  
The mean triglyceride level (125.3 mg/dL) in the HFD-M4A group was reduced 
significantly in comparison to the HFD group. However, the triglyceride concentration in 
HFD-fed mice (174.4 mg/dL) was above the normal range (71–164 mg/dL) in adult mice 
(Suckow 2001). The administration of B. breve M4A reduced plasma triglycerides to the 
normal range. This result is in line with a previous study which demonstrated lower 
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serum and liver triglyceride levels in a murine obesity model after treatment with different 
Bifidobacterium spp. strains. Bifidobacteria breve M13-4 was associated with a 
significant increase in body weight while Bifidobacteria breve L66-5 resulted in a 
decrease in body weight based on similar energy consumption (Yin et al. 2010). 
The high-fat diet used in the current study contained 44% crude fat with the same 
proportion of cholesterol as the control diet; therefore, there was no significant difference 
in serum cholesterol among the groups. In a previous study, the administration of 108 or 
109 (CFU/day) B. breve B3 in six-week-old mice for eight weeks suppressed body 
weight gain and epididymal fat, and reduced serum cholesterol (Kondo et al. 2010). This 
is in line with our data even though it occurred under different conditions—e.g. age of 
mice, diet composition, and time of treatment. 
Mice fed a HFD exhibited an altered composition of the gut microbiota and different 
levels of lactic acid bacteria. The administration of B. longum subsp. longum FA1 and B. 
breve M4A increased the proportion of lactic acid bacteria and bifidobacteria. These 
species contribute to a beneficial intestinal microbiota (Venema et al. 2003). The 
number of bifidobacteria was found inversely correlated with fat mass development by 
others already (Casas et al. 2000).  
The dose of bacteria was chosen depending on the ability of bifidobacteria to grow in 
milk aiming at the number of viable cells required to meet the probiotic definition criteria. 
Mice in the intervention groups were given a daily oral dose (106 CFU) of viable cells in 
0.2 mL, the maximum probiotic fermented milk volume that can be administered to mice 
(Minelli et al. 2008). The doses of bifidobacteria were increased in milk-supplemented 
media as much as possible. For achieving the beneficial effects of probiotics scientists 
have proposed that the product should contain probiotic bacteria with a minimum viable 
number of 106 CFU/mL and recommended 108 CFU/mL or per gram (Sukumar 2013; 
Minelli et al. 2008). Various authors have reported a low viability of Bifidobacteria in 
fermented dairy foods (Adhikari et al. 2000).The ability of organisms to grow well in milk 
depends on their ability to metabolize milk protein and lactose, and this ability varies 
considerably among strains (Ostlie et al. 2003).  
Studies in humans have confirmed oligofructose’s ability to increase the proportion of 
bifidobacteria in stools (Gibson et al. 1995). The growth of bifidobacteria showed 
improvement after the addition of (0.1 g/day per mouse) oligofructose in the drinking 
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water of both the HFD-FA1 and HFD-M4A groups. Oligofructose was applied to aid 
bacteria adherence in the mice’s intestine as the strains were of human origin. The 
dosage and duration of supplementation with oligofructose in the present study was 
lower, i.e. 0.1 g/day for six weeks compared to another study which used 0.4 g/day or 
higher for at least eight weeks (Delzenne et al. 2002). Thus, it is unlikely that the 
increase in bifidobcteria was due to oligofructose. 
The main histological characteristic of non-alcoholic fatty liver diseases is the 
accumulation of fat in the form of triglycerides in liver cells (Brunt 2010). The triglyceride 
content was measured in liver samples to investigate whether the bifidobacteria strains 
(B. longum subsp. longum FA1 and B. breve M4A) reduced hepatic fat accumulation 
and, consequently, liver weight. In the current study, only B. breve M4A reduced liver 
weight. A reduction of lipid droptlet leads to a lower risk of metabolic diseases 
(Greenberg et al. 2011).  
The accumulation of lipid droplets in Oil Red O-stained images of liver sections was 
decreased by the administration of B. breve M4A and B. longum subsp. longum FA1. 
Haematoxylin and eosin-stained images of hepatic tissue from the HFD-fed mice group 
revealed a progressive increase in steatosis. (Lee et al. 2013) evaluated the effects of 
fermented lotus extracts on inhibiting differentiation in 3T3-L1 pre-adipocytes. Different 
probiotics, including L plantarum, L rhamnosus, B. breve, and B. longum, were used 
separately. In their study the inhibition of pre-adipocyte development was examined 
using Oil red O dye staining and all groups fermented by four kinds of probiotics showed 
reduction in triglyceride deposition.  
In obese animals and humans triglyceride storage in adipocytes is increased. The 
elevated number of lipid droplets in skeletal muscle and liver cells causes hyperlipidemia 
(Greenberg et al. 2011; Lee et al. 2013). In the present study the hepatic mass of mice 
fed a high-fat diet was negatively correlated with the administration of bifidobacteria. 
Thus, oral supplementation with B. breve M4A attenuates hepatic fat accumulation. 
The quantitative analysis of liver triglycerides did not correlate to the histological 
outcome of lipid staining of the microscopic slides from liver samples. As the calculation 
of the sample size was based on weight gain and not on the liver triglyceride levels, a 
significant reduction may be observed with an higher sample sizes in future studies.  
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Dhiman et al. (2014) assessed the efficacy of a probiotic preparation that could prevent 
the recurrence of hepatic encephalopathy, reduce the number of hospitalizations, and 
diminish the severity among cirrhosis patients. The intervention used in their study 
comprised daily intake of probiotics consisting of L. acidophilus, L. paracasei, L. 
delbrueckii subsp. bulgaricus, L. plantarum, B. breve, B. infantis, B. longum and 
Streptococcus thermophiles for six months. The reduction was significant in the 
development of hepatic encephalopathy among patients receiving the probiotic in 
comparison to in the placebo group. The Child–Turcotte–Pugh and model for end-stage 
liver disease scores were used to assess the prognosis of chronic liver disease, mainly 
in patients with cirrhosis. At 24 weeks of the study, there was clinically significant 
progress in parameters among the patients treated with the probiotic  which modulated 
the gut microbiota by altering numbers, composition, and functions of bacteria, finally 
resulting in a reduction of serum ammonia levels. 
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5. Conclusion 
The isolation of bifidobacteria from infant faeces was best at 80 (mg/L) mupirocin in 
MRS media, and the shape of bifidobacteria cells was affected by mupirocin. The 
amount of bifidobacteria in the faeces of breast-fed infants increased with the 
progression of age of the infants.  
The sequencing of the 16S rRNA gene was performed for identifying the Bifidobacterium 
species. For lyophilization the cultures were harvested at pH 4 in MRS broth media. The 
survival rates of bifidobacteria after lyophilization and subsequent storage for six months 
were acceptable. The optimized protocols for bifidobacteria fermentation and 
lyophilization might be helpful for upscaling and industrial production of bifidobacteria-
supplemented food. Skimmed-milk fermentation increased the potential for acid 
production and decreased the doubling time in the presence of yeast extract, glucose, 
and oligofructose. Skimmed-milk media, supplemented with yeast extract and glucose or 
oligofructose, was effective in improving the growth of the two strains studied, 
depending on the carbohydrate concentration and the bifidobacterium strain used. The 
dietary supplementation with bifidobacteria may be helpful to reduce hepatic steatosis, 
weight gain, and elevated triglyceride serum concentrations under a high-fat diet.  
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6. Summary 
A high prevalence of overweight and obesity has been observed in the past few 
decades in many countries. Overall, policies for production of healthier foods and 
environments are recommended for the prevention of obesity. Until recently, little action 
has been taken on this issue (Swinburn et al. 2013). It has been proposed that 
alterations in the composition of the gut microbiota known as dysbiosis may be related to 
the development of obesity (Neyrinck et al. 2012). The first goal of this study was to 
isolate the predominant bifidobacterium species from the stools of breast-fed infants, 
and to identify them by their 16S rRNA genes. The strains that were identified were B. 
longum subsp. longum FA1 and B. breve M4A. The survival rates measured six months 
after lyophilisation were 74.74% and 99.6% for B. longum subsp. longum FA1 and B. 
breve M4A, respectively.  
In a second step the growth of B. breve M4A and B. longum subsp. longum FA1 was 
examined in skimmed-milk media supplemented with different levels of yeast extract and 
in combination with glucose or oligofructose. These media increased the count of the 
strains after conservation by lyophilisation. Supplementation with glucose or 
oligofructose decreased the doubling time and increased the viable cell count. Factorial 
design showed a nonlinear relationship between skimmed-milk media, bacterial count 
number and acid production indicating an opposite impact of yeast extract with the 
supplementation of glucose or oligofructose in skimmed-milk media.  
Response surface plots were applied to optimize the supplemented skimmed-milk 
media. Both strains grew more rapidly in supplemented media than in the skimmed milk-
based medium alone. The fermentation in skimmed milk was dependent on nutrient 
availability and the carbon source. The addition of yeast extract with glucose or 
oligofructose to skimmed milk increased the growth rate and acid production, compared 
with skimmed milk alone, when incubated anaerobically at 37C for 48 hours. Acid 
production was higher in B. breve M4A than in B. longum subsp. longum FA1 when 
inoculated into skimmed milk supplemented with yeast extract with glucose or 
oligofructose. 
The second goal of the study was to evaluate the in vivo anti-obesity effect of B. breve 
M4A and B. longum subsp. longum FA1 in young mice fed an high-fat diet (HFD). Three 
(male mice C57BL/6JRj) groups, the model HFD group and treatment (HFD-FA1 and 
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HFD-M4A) groups were fed an HFD to induce obesity. After feeding the mice a HFD for 
six weeks, animals receiving B. breve M4A (4.1 × 106 CFU/mL) and B. longum subsp. 
longum FA1 (2.9 × 106 CFU/mL) had significantly lower (p < 0.01) weight gain compared 
to mice fed a high-fat diet only. Mice fed B. breve M4A supplemented with 0.3% yeast 
extract and 3% glucose exhibited significantly lower serum triglycerides (p < 0.05) 
compared with the HFD group. The daily consumption (2.9×106 CFU/day) of B. longum 
subps. longum FA1 and (4.1×106 CFU/day) B. breve M4A (p < 0.01) significantly 
increased the amount of bifidobacteria and lactic acid bacteria in the large intestine.  
This study showed that Bifidobacterium species and their acid-production reduced 
weight gain and energy metabolism. Thus, bifidobacteria supplementation may be one 
mean for reducing obesity and related chronic Non-commuicable diseases. 
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7. Zusammenfassung 
In den vergangenen Jahrzehnten wurde in vielen Ländern eine steigende Prävalenz von 
Übergewicht und Adipositas beobachtet. Allgemein werden zur Adipositasprävention 
sowohl die Herstellung gesundheitsfördernder Lebensmittel als auch eine 
gesundheitsfördernde Umwelt empfohlen. Dennoch sind bisher wenige erfolgreiche 
Maßnahmen implementiert worden (Swinburn et al. 2013).  
Es wurde vermutet, dass Veränderungen in der Zusammensetzung der Darmmikrobiota, 
bekannt als Dysbiose, mit der Entstehung von Adipositas zusammenhängen (Neyrinck 
et al. 2012).  
Erstes Ziel der vorliegenden Studie war, vorherrschende Bifidobacterium-Arten aus dem 
Stuhl von gestillten Säuglingen zu isolieren und anhand ihrer 16S rRNA Gene zu 
identifizieren. Gefunden wurden B. longum subsp. longum FA1 und B. breve M4A. Die 
Überlebensrate der Bakterien, gemessen sechs Monate nach Lyophilisierung, lag bei 
74.74% für B. longum subsp. longum FA1 beziehungsweise 99.6% für B. breve M4A.  
Dann wurde das Wachstum von B. breve M4A und B. longum subsp. longum FA1 in 
Magermilch-Medien untersucht, die mit verschiedenen Konzentrationen von an 
Hefeextrakt in Kombination mit Glucose oder Oligofructose angereichert waren. Diese 
Medien erhöhten die Anzahl an Stämmen nach Konservierung mittels Lypophilisierung. 
Die Supplementation verkürzte die Verdopplungszeit und erhöhte die Anzahl der 
lebensfähigen Zellen. Der faktorielle Versuchsplan zeigte eine nicht lineare Beziehung 
zwischen Magermilch-Medien, Bakterienanzahl und Säureproduktion. Dies deutet auf 
eine gegensätzliche Auswirkung von Hefeextrakt mit Glucose- oder Oligofructose-
Supplementation in Magermilch-Medien hin. Response Surface Plots wurden 
angewandt, um die supplementierten Magermilch-Medien zu optimieren. Beide Stämme 
wuchsen schneller in supplementierten Medien als in Medien auf Magermilchbasis 
alleine. Die Säureproduktion lag höher bei B. breve M4A als bei B. longum subsp. 
longum FA1, wenn sie in Magermilch supplementiert mit Hefeextrakt sowie Glucose 
oder Oligofructose inokuliert wurde. Die Fermentationsfähigkeit in Magermilch hing von 
Nährstoffverfügbarkeit und der Kohlenstoffquelle ab.  
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Weiteres Ziel der Studie war es, die Anti-Adipositas Aktivität von B. breve M4A und B. 
longum subsp. longum FA1 an jungen Mäusen, denen eine fettreiche Nahrung gefüttert 
wurde, zu untersuchen. Drei (Male mice C57BL/6JRj) Gruppen, einer Kontroll-HFD-
Gruppe und beiden interventionsgruppen (HFD-FA1 und HFD-M4A) wurde eine 
fettreiche Nahrung gefüttert, um Adipositas hervorzurufen. Nach einem Zeitraum von 
sechs Wochen zeigten Mäuse, die B. breve M4A (4.1 × 106 CFU/day) und B. longum 
subsp. longum FA1 (2.9 × 106 CFU/day) erhalten hatten, einen statistisch signifikant 
niedrigeren (p < 0.01) Gewichtszuwachs im Vergleich zu Mäusen, die nur die fettreiche 
Nahrung erhielten. Mäuse, die mit B. breve M4A, welches mit 0.3% Hefeextrakt und 3% 
Glucose angereichert war, gefüttert wurden, wiesen signifikant niedrigere Serum 
Triglyceride (p < 0.05) auf im Vergleich zu der HFD Gruppe. Täglicher Konsum (2.9×106 
CFU/day) von B. longum subps. longum FA1 und (4.1×106 CFU/day) B. breve M4A 
erhöhte signifikant (p < 0.01) die Anzahl an Bifidobakterien und zu den 
Milchsäurebakterien im Dickdarm.  
Die Untersuchungen zeigen, dass die geringere Gewichtszunahme, die günstigeren und 
die geringere Fettspeicherung in der Leber von der Gabe der untersuchten 
Bifidobakterien und deren Säureproduktion günstig beeinflusst wurden. Demzufolge 
erscheint eine Anreicherung der Nahrung mit Solchen als förderlich, um Adipositas und 
damit zusammenhängende Gesundheitsfolgen zu vermeiden.  
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